>
volge

Everything but Scale : State of Play of Digital Health in the GCC

GCC DIGITAL HEALTH · STATE OF PLAY 2026
A rich payer, bottomless sovereign capital, state-built platforms and top-down mandates: the Gulf has every ingredient digital health needs, except the one it cannot buy.
61.2M
people, six markets
$36M
GCC health-tech VC, 2025
242+
hospitals, one virtual
GCC 2026

State of Play is a read on a sector: its size, its structure, where the money moves and what moves it. Each edition takes one market and sets out what is known, what is claimed, and what the difference between the two is worth to anyone deciding where to commit.

A rich payer, bottomless sovereign capital, state-built platforms and top-down mandates: the Gulf has every ingredient digital health needs, except the one it cannot buy. The Gulf’s digital-health market read in full: the payer and the platforms that make it the envy of the emerging world, and the scale it cannot reach.

Figures carry their basis and their date. Where published estimates disagree, the range is given and the basis named rather than averaged away, and where a widely quoted number does not survive checking it is corrected here rather than repeated. Every chart plots a figure stated in the text, and nothing is projected beyond what a named source projects.

Contents

01Introduction
  1. 02Everything digital health needs, except the thing it cannot buy
  2. 05Everything but scale
  3. 06A market sized carefully
  4. 08The payer advantage
  5. 09The demand the platforms serve
  6. 10The scale problem
  7. 11Six markets, six regulators
02Deep dive
  1. 14Government as builder and payer
  2. 15Seha Virtual Hospital
  3. 16The records and the exchanges
  4. 18Sovereign capital and compute
  5. 19The data-localisation walls
  6. 21Telehealth, licensed and paid
  7. 22AI: where the Gulf leads
03Real-world application
  1. 24The sovereign super-apps
  2. 25M42 and Med42: the AI champion
  3. 26PureHealth: scale by acquisition abroad
  4. 27The thin startup layer
  5. 29The funding gap
  6. 30The crowding-out question
  7. 32Saudi Arabia: the platform state
  8. 33The UAE: the hub
  9. 34Qatar and the smaller states
  10. 36The capital and the deals
04The read
  1. 39Why scale cannot be bought
  2. 40Two of six markets
  3. 42The constraints beyond scale
  4. 43Market access, and what could go wrong
  5. 44The next two to three years
  6. 46The read, on a page
  7. 47Key takeaways
  8. 48Volge's expertise in digital health
  9. •Sources
Digital HealthState of Play01 •

Everything digital health needs, except the thing it cannot buy

One inversion drives everything that follows: the Gulf has solved the problems that gate digital health everywhere else, and is left with the one problem money cannot solve.

In most of the world, di­gital health is throttled by two things: no payer will­ing to fund it, and no cap­ital to build it. The Gulf has solved both. It has a rich in­sti­tu­tional payer, uni­ver­sal state care plus man­dat­ory in­sur­ance, with tele­health re­im­bursed at the same rate as an in-per­son visit. It has bot­tom­less sov­er­eign cap­ital and some of the largest AI com­pute on the planet. Its gov­ern­ment-built plat­forms are among the best any­where, from the biggest vir­tual hos­pital on earth to na­tional health-re­cord ex­changes. De­mand is acute, driven by one of the heav­iest dis­ease bur­dens any­where. The Gulf has every in­gredi­ent di­gital health needs, ex­cept scale.

That one miss­ing in­gredi­ent de­cides the rest, be­cause it is the only one sov­er­eign cap­ital can­not buy. The en­tire six-state Gulf holds about 61.2 mil­lion people, a fifth of the United States, a twenty-third of India, split across six sep­ar­ately-reg­u­lated mar­kets with in­com­pat­ible data re­gimes, and dom­in­ated by a tran­si­ent, ex­pat­ri­ate-heavy pop­u­la­tion. Three con­sequences run off that arith­metic.

  • The payer and cap­ital prob­lems are solved. What cripples di­gital health in India or Africa (no one to pay, no money to build) simply does not apply in the Gulf.
  • Scale is the bind­ing con­straint. Small pop­u­la­tions across frag­men­ted, sep­ar­ately-reg­u­lated mar­kets cap the user num­bers any con­sumer health-tech busi­ness can reach, and ven­ture eco­nom­ics de­pend on scale.
  • Value con­cen­trates in the sov­er­eign and the AI layer. Be­cause private con­sumer scale is capped, value ac­crues to gov­ern­ment-built plat­forms and to the AI layer, where the Gulf’s cap­ital and com­pute genu­inely lead.

The Gulf is thus the best-re­sourced di­gital-health mar­ket in the emer­ging world and the hard­est place in it to scale a private com­pany. Value goes to who­ever builds for the sov­er­eign and the AI layer, not to any­one chas­ing con­sumer scale the pop­u­la­tion can­not sup­ply.

The in­ver­sion holds, though the basis on which it was first ar­gued has moved. The move­ment sharpens the con­clu­sion. Mar­ket Re­search Fu­ture re-cut its GCC di­gital-health series in 2026, from about US$5.41 bil­lion com­pound­ing at roughly 21 per cent a year to about US$6.28 bil­lion in 2025 (Mar­ket Re­search Fu­ture, 2026). The re­vised series rises to about US$23.8 bil­lion by 2035 at about 14.2 per cent. The level is higher and the com­pound­ing is slower, so the ter­minal mar­ket im­plied for 2035 is smal­ler than the earlier basis sug­ges­ted. Growth above 20 per cent sur­vives only at coun­try level, where Saudi Ar­a­bia is put at about 22 per cent to 2032 and the UAE at about 23 per cent to 2035. A re­gion com­pound­ing at 14

Digital HealthState of Play02 •

per cent rather than 21 per cent has less room to grow out of its scale con­straint, not more.

Growth above 20 per cent survives only at country level
per cent a year
06.212.518.82514.2GCC, to 203522Saudi Arabia, to 203223UAE, to 2035
Source: Market Research Future, 2026

The plat­form evid­ence has moved too. Seha Vir­tual Hos­pital, re­launched in March 2025, con­nects 241 hos­pit­als and more than 1,400 health centres (Saudi Min­istry of Health, 9 Au­gust 2026). That is a wider foot­print than the hos­pital count alone con­veys, and a cor­rec­tion to the 242-hos­pital fig­ure car­ried earlier in this series. Above it sit the cit­izen front-ends, Se­h­haty, Mawid and the 937 ser­vice, and in the UAE three in­ter­con­nec­ted ex­changes through which roughly 1.9 bil­lion re­cords are ac­cess­ible (Malaffi, NABIDH and Riay­ati, 2026).

The payer is ar­riv­ing un­evenly. Com­puls­ory cover took ef­fect in the UAE on 1 Janu­ary 2025 and Saudi Ar­a­bia re­quires Coun­cil of Health

In­sur­ance-com­pli­ant cover from every private em­ployer, but Bahrain's SEHATI and Oman's Dham­ani are still phas­ing in rather than fully in force. The payer ad­vant­age is real in two mar­kets and pro­spect­ive in the oth­ers, the same two-mar­ket con­cen­tra­tion the scale ar­gu­ment de­scribes.

Digital HealthState of Play03 •

The part in brief

  1. 01The payer and the capital are both in place, yet the six states together hold only about 61.2 million people, a fifth of the United States.
  2. 02Market Research Future re-cut the regional series in 2026 to about US$6.28 billion for 2025, reaching about US$23.8 billion by 2035 at 14.2 per cent.
  3. 03Rates above 20 per cent now hold only for Saudi Arabia, put at about 22 per cent to 2032, and the UAE, at about 23 per cent to 2035.
  4. 04The public platform is wider than the hospital count suggests: 241 hospitals and over 1,400 health centres, which corrects the 242 figure carried earlier.
  5. 05Roughly 1.9 billion records are reachable through three UAE exchanges, where compulsory cover took effect on 1 January 2025, ahead of the smaller states.
Digital HealthState of Play04 •
01

The Problem

A market with every advantage but one, and the one it lacks is decisive.

Everything but scale

The Gulf is the mirror image of every other emerging digital-health market, and its problem is the exact opposite one.

The Gulf in­verts the usual emer­ging-mar­ket story. Else­where, in India, across Africa, the con­straint sits on the de­mand side. Pa­tients pay out of pocket and no payer funds the care. Cap­ital is scarce, and the unit eco­nom­ics never work no mat­ter how vast the pop­u­la­tion. The Gulf has the op­pos­ite pro­file. Its de­mand side is the strongest in the world. A state-and-in­surer payer funds di­gital care, sov­er­eign cap­ital is in near-lim­it­less sup­ply, and gov­ern­ment plat­forms are built top-down at na­tional scale. By every meas­ure that throttles di­gital health else­where, the Gulf is rich.

And yet it has its own, op­pos­ite con­straint. What the Gulf lacks is not money or a payer but people, or, more ex­actly, scale. The whole re­gion is a mar­ket of 61.2 mil­lion, smal­ler than many single coun­tries, and it is not even one mar­ket but six, each with its own reg­u­lator, data re­gime and rules. The very thing that makes a con­sumer health-tech com­pany valu­able, the abil­ity to win tens of mil­lions of users cheaply and grow into a vast ad­dress­able mar­ket, is pre­cisely what the Gulf can­not offer. The re­gion has every ad­vant­age but one, and the one it lacks gov­erns the use it can make of the rest.

Three struc­tural mod­els frame the in­ver­sion, not two. The United States runs a payer-led mar­ket. Its bind­ing con­straint is cost. India runs pub­lic

Elsewhere, digital health lacks a payer and capital. The Gulf has both in abundance, and lacks only scale, the one thing money cannot buy.
Key takeaways
  • The Gulf in­verts the usual story: rich payer, rich cap­ital, top-down plat­forms, but small mar­kets.
  • The whole GCC is 61.2m people across six sep­ar­ately-reg­u­lated states.
  • Scale is the bind­ing con­straint: the one in­gredi­ent sov­er­eign cap­ital can­not buy.

rails without a dom­in­ant payer, so its con­straint is unit eco­nom­ics. The Gulf runs a payer-by-man­date along­side a state-built plat­form, and its con­straint is scale and frag­ment­a­tion (Volge ana­lysis, 2026). The Gulf's dif­fi­culty is there­fore not a weaker ver­sion of the In­dian prob­lem but a dif­fer­ent prob­lem. It is the only one of the three that le­gis­la­tion, re­im­burse­ment design and cap­ital de­ploy­ment can­not ad­dress.

The de­mand side can be meas­ured. Gross do­mestic product per head across the six states runs between about US$23,000 and US$81,000, with near-uni­ver­sal smart­phone use. Ad­op­tion, where it has been stud­ied, is high. Re­ten­tion across di­gital-health app cat­egor­ies in Saudi Ar­a­bia and the UAE has been put at 64 to 87 per cent, with e-phar­macy the

Digital HealthState of Play05 •

most-used solu­tion in both mar­kets (McKinsey, cited 2026). A pop­u­la­tion that is wealthy, con­nec­ted and will­ing to use the ser­vices is the pre­con­di­tion most emer­ging mar­kets lack.

What is lack­ing is ag­greg­a­tion, and the count of bor­ders is higher than the count of states. The six mar­kets are gov­erned by seven health reg­u­lat­ors and three sep­ar­ate health-data re­gimes, so a re­gional plat­form must li­cense, in­teg­rate and com­ply sev­eral times over be­fore it reaches the users any single mar­ket can sup­ply. The arith­metic is there­fore strong de­mand, a solved payer, abund­ant cap­ital, and a mar­ket that must be as­sembled state by state rather than entered once.

A market sized carefully

The Gulf digital-health market is real and growing fast, provided it is not mistaken for the much larger region around it.

An­chor the Gulf di­gital-health mar­ket at about $6.3 bil­lion in 2025, on its way to roughly $24 bil­lion by 2035 at about 14% a year, with telemedi­cine a smal­ler slice near $530 mil­lion and e-health around $2.7 bil­lion. Healthy growth, un­der­writ­ten by the build-out and the payer. But the single most im­port­ant dis­cip­line in siz­ing this mar­ket is geo­graphic: the GCC is not the Middle East, and not the wider MEA re­gion.

The dis­tinc­tion mat­ters be­cause the big­ger la­bels pro­duce big­ger num­bers that get routinely mis­la­belled. The “Middle East” di­gital-health mar­ket is put near $14 bil­lion in 2025, and MEA higher still. Those fig­ures fold in Egypt, Iran, Africa and more. They must never pass for Gulf. Within the GCC it­self, Saudi Ar­a­bia and the UAE dom­in­ate, to­gether some 83% of re­gional health spend­ing. The hon­est fram­ing is a mod­est but fast-grow­ing mar­ket, around $6 bil­lion today. Its ap­par­ent size is often in­flated by re­gional con­fu­sion, and its real ceil­ing is set not by growth rates but by the pop­u­la­tion be­hind the num­bers.

The siz­ing basis used here is it­self a cor­rec­tion. The series on which this read's cent­ral ar­gu­ment was built, roughly US$5.41 bil­lion com­pound­ing at about 21 per cent a year, has been su­per­seded. Mar­ket Re­search Fu­ture re-cut the same GCC series in 2026 to about US$5.5 bil­lion in 2024 and about US$6.28 bil­lion in 2025, reach­ing about US$23.8 bil­lion by 2035 at about 14.2 per cent. The con­sequence for the ar­gu­ment is real. Com­pound­ing at 14 per cent rather than 21 per cent, the re­gion reaches a smal­ler mar­ket in 2035 than pre­vi­ously pro­jec­ted. The claim that Gulf di­gital health com­pounds above 20 per cent now holds only for Saudi Ar­a­bia, at about 22 per cent to 2032, and the UAE, at about 23 per cent to 2035.

Be­neath the head­line the seg­ment series di­verge, and they must not be added to­gether. GCC e-health is put at about US$2.7 bil­lion in 2024, rising to about US$10.0 bil­lion by 2033 at about 15.6 per cent. E-phar­macy is put at about US$2.37 bil­lion in 2024, rising to about US$9.44 bil­lion by 2033 at

Digital HealthState of Play06 •
GCC digital health, re-based series
US$ bn
06.212.518.8255.520246.3202523.82035
Source: Market Research Future, 2026

about 15.4 per cent. Tele­health, the fast­est slice, runs from about US$0.44 bil­lion in 2024 to about US$2.6 bil­lion by 2033 at about 21.9 per cent (IMARC and Pre­ced­ence Re­search, 2024 to 2026). The scopes over­lap sub­stan­tially. A reader who sums them will double-count.

Telehealth grows fastest and still stays the smallest slice in 2033
US$ bn, 2033
E-health10E-pharmacy9.4Telehealth2.6
Source: IMARC and Precedence Research, 2024 to 2026
The three segment series start from very different bases in 2024
US$ bn, 2024
00.81.52.232.7E-health2.4E-pharmacy0.4Telehealth
Source: IMARC and Precedence Research, 2024 to 2026

The hon­est po­s­i­tion is a range, not a point, and a scope stated rather than im­plied. Pub­lished GCC es­tim­ates for 2025 sit between about US$5.5 bil­lion and US$6.3 bil­lion, and the growth rate sits between about 14 and 22 per cent, de­pend­ing on whether the whole re­gion or only its two lead­ing mar­kets is being meas­ured.

That ad­vant­age runs straight into di­gital health, be­cause the payer pays for vir­tual care. Dubai re­im­burses a telemedi­cine con­sulta­tion at the same rate as an in-per­son one, and Abu Dhabi pays a flat fee per visit. Saudi Ar­a­bia builds tele­health into its pub­lic sys­tem. The con­trast with India is the whole thesis in a single fact. In­dian di­gital-health com­pan­ies can­not get any­one to pay for the out­pa­tient con­sulta­tion they sell, whereas Gulf tele­health is re­im­bursed by in­surers and the state at par­ity. The

Digital HealthState of Play07 •

unit-eco­nom­ics ceil­ing that crushes di­gital health else­where simply does not exist here. The payer prob­lem is solved. That makes the scale prob­lem which re­mains all the more strik­ing.

The payer advantage

The Gulf has the one thing Indian digital health would trade almost anything for: somebody other than the patient who pays.

The Gulf’s de­fin­ing ad­vant­age, and its sharpest con­trast with other emer­ging mar­kets, is its payer. Across all six states, the gov­ern­ment funds uni­ver­sal care for cit­izens, and man­dat­ory em­ployer-paid in­sur­ance cov­ers the large res­id­ent pop­u­la­tion; from Janu­ary 2025 the UAE com­pleted its rol­lout, so every emir­ate now en­forces com­puls­ory cover. Out-of-pocket spend­ing sits in the low teens as a share of health ex­pendit­ure, around 16% in Saudi Ar­a­bia, 13% in the UAE, single di­gits in Oman, against 50 to 60% in India. The pa­tient is not the payer.

Quick facts: the payer
Out-of-pocket spend (Saudi / UAE / Oman)16% / 13% / 7%
India out-of-pocket (contrast)~50–60%
UAE mandatory cover, all emiratesJan 2025
Dubai telehealth reimbursementAt parity
In the Gulf the patient is not the payer
% of health expenditure paid out of pocket
India50Saudi Arabia16UAE13
Source: national health authorities, 2026

Gulf states are le­gis­lat­ing the payer into ex­ist­ence, and at dif­fer­ent speeds. Saudi Ar­a­bia re­quires Coun­cil of Health In­sur­ance-com­pli­ant cover from every private em­ployer. The king­dom's man­date is there­fore already op­er­at­ive, and not, as earlier drafts of this series im­plied, await­ing a 2026 pro­gramme. Bahrain's SEHATI was es­tab­lished under Law 23 of 2018 and car­ries an al­loc­a­tion of BD 688 mil­lion against roughly 686,000 ex­pat­ri­ate res­id­ents and their de­pend­ants. Oman's Dham­ani launched its plat­form on 1 Janu­ary 2025. Both are still phas­ing in. Neither is yet fully in force (na­tional health au­thor­it­ies, 2026). The payer ad­vant­age is there­fore com­plete in two mar­kets and par­tial in the re­main­ing four.

The ad­vant­age mon­et­ises through the claim, not the con­sulta­tion, and the claims rail is being en­forced. Dubai's eClaimLink, re­in­forced by dir­ect­ive PD-05-2025, re­quires elec­tronic claims sub­mis­sion under defined timelines with pen­al­ties for fail­ure, which makes in­teg­ra­tion with the claims layer a con­di­tion of being paid rather than an op­tim­isa­tion. Premium

Digital HealthState of Play08 •

growth con­firms the widen­ing pool: UAE health premi­ums rose about 12.7 per cent in the first half of 2025.

Value is ac­cru­ing ac­cord­ingly. Health in­sur­tech and claims is the strongest seg­ment in Gulf di­gital health, pre­cisely be­cause the man­date cre­ated the coun­ter­party. Klaim, a pro­vider claims-fintech, raised a US$26 mil­lion Series A in 2025. Se­hteq, an ar­ti­fi­cial-in­tel­li­gence-led health in­surer, re­ports more than 700,000 cus­tom­ers (com­pany dis­clos­ures, 2025 to 2026). The les­son for an entrant is that the payer is reached through the claim, the em­ployer and the in­surer, not through the pa­tient.

The demand the platforms serve

Behind the payer sits a population that needs digital health: sick, and short of the clinicians to treat it.

The de­mand for di­gital health in the Gulf is not man­u­fac­tured by policy. It comes from a real and acute clin­ical need. The re­gion car­ries one of the heav­iest chronic-dis­ease bur­dens in the world, dia­betes pre­val­ence among the highest any­where, Saudi Ar­a­bia at 23.1% of adults, Kuwait at 25.6%, and non-com­mu­nic­able dis­eases be­hind the large ma­jor­ity of all deaths. That bur­den de­mands ex­actly what di­gital health sup­plies. Chronic-dis­ease man­age­ment and re­mote mon­it­or­ing are wanted, as are reg­u­lar tele­con­sulta­tion and AI-as­sisted screen­ing.

Com­pound­ing the need is a short­age of clini­cians. The Gulf runs below de­veloped-world phys­i­cian and nurse dens­it­ies, and its health work­force is over­whelm­ingly ex­pat­ri­ate, in the UAE, an es­tim­ated 82% of phys­i­cians and 96% of nurses; in Saudi Ar­a­bia, around 90% of private-sec­tor health staff. A pop­u­la­tion this sick, served by a work­force this stretched and this mo­bile, is the strongest pos­sible case for di­gital health. Telemedi­cine stretches scarce doc­tors across dis­tance, and re­mote mon­it­or­ing man­ages chronic dis­ease without a clinic visit. AI mul­ti­plies clin­ical ca­pa­city. The de­mand side is as com­pel­ling as the payer side. The Gulf needs di­gital health, can pay for it, and is build­ing it, which is what makes the scale con­straint so cent­ral.

Dia­betes pre­val­ence across the Gulf now runs from 18.7 to 25.6 per cent of adults against a global 11.1 per cent, on the In­ter­na­tional Dia­betes Fed­er­a­tion's 11th edi­tion, pub­lished in 2025 on 2024 es­tim­ates. That su­per­sedes the 9th-edi­tion fig­ures on which earlier Gulf reads were built, where the range was roughly 15 to 22 per cent. The re-base also re-or­ders the re­gion. Qatar, at 24.6 per cent, now ranks second, ahead of Saudi Ar­a­bia. Bahrain is at 22.1 per cent and the UAE at 20.7 per cent, with Oman, re-based most steeply of all, at 18.7 per cent.

The bur­den is there­fore heav­ier, and more evenly dis­trib­uted, than the earlier fig­ures sug­ges­ted. No Gulf state now sits below about 19 per cent, which means chronic-dis­ease de­mand is a re­gional con­di­tion rather than a Kuwaiti and Saudi one, and it falls on health sys­tems whose clin­ical work­force is largely im­por­ted and con­tested.

Digital HealthState of Play09 •
Diabetes prevalence among adults, re-based
per cent of adults
Kuwait25.6Qatar24.6Saudi Arabia23.1Bahrain22.1UAE20.7Oman18.7World11.1
Source: International Diabetes Federation, 11th edition, 2025

The de­mand pulls two things spe­cific­ally. Re­mote mon­it­or­ing and chronic-care man­age­ment is the fast­est-grow­ing edge of Gulf di­gital health, drawn dir­ectly by the dia­betes bur­den, and it is the seg­ment where con­tinu­ous en­gage­ment is now mon­et­is­able be­cause the ar­riv­ing payer re­im­burses it. Clin­ical ar­ti­fi­cial in­tel­li­gence is the second draw, for the same reason in re­verse. The con­straint it re­lieves is a short­age of clini­cians, not a short­age of pa­tients. The de­mand side of this mar­ket does not need to be cre­ated, only served and billed. The second part is the de­cis­ive one.

Scale mat­ters be­cause con­sumer health-tech eco­nom­ics de­pend on it. The ven­ture model runs on win­ning users cheaply and grow­ing into a vast mar­ket, spread­ing the high fixed costs of tech­no­logy and reg­u­la­tion across tens or hun­dreds of mil­lions of them. In the Gulf the user num­bers

are capped by demo­graphy, so the fixed costs can­not be amort­ised the same way, and the re­turns that jus­tify ven­ture cap­ital are harder to reach. The pop­u­la­tion com­pounds the prob­lem: it is heav­ily ex­pat­ri­ate and tran­si­ent, nearly 90% of the UAE and Qatar are non-na­tion­als, many of whom leave, which makes the user base small and un­stable. The Gulf can fund and build di­gital health su­perbly. What it can­not do is provide the scale that makes a private di­gital-health com­pany valu­able.

The scale problem

Every advantage the Gulf has runs into one wall: there are not enough people, and they are not in one market.

Scale is the con­straint that defines this mar­ket, and the num­bers are stark. The whole six-state Gulf holds about 61.2 mil­lion people, roughly a fifth of the United States, a twenty-third of India. Saudi Ar­a­bia, at 35.3 mil­lion, is the only large na­tional mar­ket, and the UAE has about 11.4 mil­lion. The other four are small. Oman and Kuwait hold around 5 mil­lion each, Qatar 3.2 mil­lion and Bahrain 1.6 mil­lion. For a di­gital-health com­pany this is a hard ceil­ing. The ad­dress­able pop­u­la­tion is a frac­tion of what a com­par­able busi­ness in India, the United States or In­done­sia can reach.

The scale con­straint can be read dir­ectly in the cap­ital that reaches the sec­tor, which is the mar­ket's own ver­dict on its size. Dis­closed GCC

Digital HealthState of Play10 •

health-tech­no­logy in­vest­ment amoun­ted to about US$148 mil­lion across 32 star­tups between Janu­ary 2025 and July 2026, com­pris­ing 21 rounds in 2025 and 11 in the first half of 2026. Saudi Ar­a­bia ac­coun­ted for 17 of the com­pan­ies and the UAE for 11 (PitchBook, via WHX Tech, 2026). In the same period MENA star­tups across all sec­tors raised about US$2.1 bil­lion in the first half of 2025 alone, up about 134 per cent year on year. Cap­ital is plen­ti­ful in the re­gion. In this sec­tor it is scarce. That is a state­ment about ad­dress­able scale rather than about ap­pet­ite.

Two markets account for most of the funded GCC health-technology companies
companies funded, Jan 2025 to Jul 2026
01020304032All GCC17Saudi Arabia11UAE
Source: PitchBook, via WHX Tech, 2026

The reg­u­lat­ory arith­metic com­pounds the demo­graphic arith­metic. The six mar­kets carry seven health reg­u­lat­ors and three sep­ar­ate health-data re­gimes, so the fixed cost of li­cens­ing, ex­change in­teg­ra­tion and data res­id­ency is in­curred re­peatedly while the user base it un­locks is added in small

in­cre­ments. A plat­form that would be built once for a single large mar­ket must here be built, cer­ti­fied and hos­ted sev­eral times for the same ag­greg­ate pop­u­la­tion.

Dis­tri­bu­tion fol­lows from that struc­ture. Dir­ect-to-con­sumer in the Gulf is vi­able only for premium or spe­cialty pro­pos­i­tions, or for a plat­form already op­er­at­ing at re­gional scale, be­cause ac­quis­i­tion cost is high and the do­mestic audi­ence in any one state is small. Re­gional ag­greg­a­tion is not a growth am­bi­tion here but the min­imum con­di­tion of vi­ab­il­ity.

Six markets, six regulators

The 61 million is not even one market. It is six, and the borders between them are real.

The scale prob­lem is worse than the head­count alone sug­gests, be­cause the 61.2 mil­lion is not a single mar­ket. It is six. Each is a sov­er­eign state with its own health reg­u­lator and li­cens­ing re­gime. More de­cis­ively, each has its own data-pro­tec­tion and data-loc­al­isa­tion rules. A di­gital-health com­pany can­not build once and serve the re­gion. It has to re­gister, li­cense and com­ply sep­ar­ately in Saudi Ar­a­bia, the UAE, Qatar, Kuwait, Oman and Bahrain. Within the UAE alone it faces three on­shore health reg­u­lat­ors and two fur­ther free-zone data re­gimes.

Digital HealthState of Play11 •

The frag­ment­a­tion hits di­gital health in a spe­cific, dam­aging way. Un­like phys­ical goods, di­gital health runs on data, and the Gulf states re­quire health data to stay within na­tional bor­ders. A single re­gional plat­form, shar­ing re­cords and serving pa­tients across the six mar­kets, is there­fore not leg­ally straight­for­ward. The nat­ural scale eco­nomy that would let a Gulf com­pany ag­greg­ate the re­gion into one ad­dress­able mar­ket is blocked by the re­gion’s own in­ternal data bor­ders. Even the mod­est 61 mil­lion is sliced into six smal­ler pools. They are not equal. Two of them (Saudi Ar­a­bia and the UAE) hold most of the value, and four are too small to an­chor a busi­ness alone. Frag­ment­a­tion, layered on small pop­u­la­tions, is what turns a scale dis­ad­vant­age into a scale wall.

Seven health reg­u­lat­ors and three sep­ar­ate health-data re­gimes gov­ern the six states. That is a higher count of bor­ders than the head­line six im­plies, and the fig­ure that mat­ters to any­one budget­ing an entry. The ad­di­tional reg­u­lator arises from the UAE's di­vi­sion of health au­thor­ity between the fed­eral min­istry and the emir­ate-level au­thor­it­ies. In­teg­ra­tion ob­lig­a­tions fol­low the same di­vi­sion. A telemedi­cine plat­form must con­nect to NABIDH in Dubai, to Malaffi in Abu Dhabi and to Riay­ati na­tion­ally. The rel­ev­ant ex­change is de­term­ined by where the pa­tient is treated rather than by where the com­pany is dom­i­ciled.

The frag­ment­a­tion is one of mul­ti­pli­city rather than of legal un­cer­tainty, and that dis­tinc­tion is to the Gulf's credit. In­dian e-phar­macy, by con­trast, has op­er­ated without a no­ti­fied frame­work. The Gulf re­gimes are writ­ten,

in force and en­forced. The Saudi Food and Drug Au­thor­ity in­tro­duced man­dat­ory li­cens­ing and pre­scrip­tion con­trols for on­line phar­ma­cies in 2023, and tele­health is li­censed na­tion­ally in each state under pub­lished prac­tice rules. An entrant faces a known set of ob­lig­a­tions re­peated six or seven times, which is a more nav­ig­able prob­lem than an un­known set re­peated once.

The cost, how­ever, is cu­mu­lat­ive and per­man­ent. Each re­gime re­quires its own li­cence, its own in­teg­ra­tion and, where data res­id­ency ap­plies, its own host­ing, so the com­pli­ance bur­den scales with the num­ber of mar­kets entered rather than with the num­ber of pa­tients served. It is the clearest reason why the win­ning Gulf model ag­greg­ates de­lib­er­ately across the re­gion from the out­set rather than ex­pand­ing into it op­por­tun­ist­ic­ally.

The scale problem is worse than the headcount alone suggests, because the 61.2 million is not a single market.
Digital HealthState of Play12 •

The part in brief

  1. 01Saudi Arabia holds 35.3 million people and the UAE about 11.4 million, with the remaining four states between 1.6 and 5 million each.
  2. 02The regional market is re-based to about US$6.28 billion for 2025 and about US$23.8 billion for 2035, a slower path than the superseded 21 per cent basis.
  3. 03Patients fund little of the care: out-of-pocket spending is near 16 per cent in Saudi Arabia and 13 in the UAE, against 50 to 60 per cent in India.
  4. 04Adult diabetes now runs from 18.7 to 25.6 per cent against a global 11.1 per cent, and no Gulf state sits below about 19 per cent.
  5. 05Seven regulators and three health-data regimes govern six markets, and disclosed health-technology funding reached only about US$148 million across 32 startups.
Digital HealthState of Play13 •
The Problem

Elsewhere, digital health lacks a payer and capital. The Gulf has both in abundance, and lacks only scale, the one thing money cannot buy.

02

The Machine

The sovereign platforms, the compute, and the rules that build and bound the market.

Government as builder and payer

In the Gulf, the state does not just fund digital health or regulate it. It builds it, and that changes the whole market structure.

The de­fin­ing struc­tural fea­ture of Gulf di­gital health is that the gov­ern­ment is the payer, the reg­u­lator and the builder. In most mar­kets private com­pan­ies build the plat­forms, while the state at most pays or reg­u­lates. In the Gulf the state it­self con­structs the di­gital-health in­fra­struc­ture at na­tional scale, the vir­tual hos­pit­als, the super-apps, the na­tional elec­tronic health re­cords and ex­changes. The same sov­er­eign that funds the care also owns the plat­form de­liv­er­ing it.

This top-down model is the Gulf’s an­swer to the scale prob­lem. It is a power­ful one. A gov­ern­ment does not need ven­ture-scale user eco­nom­ics to jus­tify a plat­form. It can de­ploy one na­tion­ally by man­date, fund it from sov­er­eign budgets, and re­quire fa­cil­it­ies and cit­izens to use it. So the plat­forms that would, else­where, be built by ven­ture-backed star­tups ra­cing for scale are, in the Gulf, built by the state for the whole pop­u­la­tion at once. The most valu­able di­gital-health as­sets in the Gulf are there­fore gov­ern­ment-owned, and the private star­tup layer is cor­res­pond­ingly thin. The stra­tegic ques­tion for any com­mer­cial player is how to build with,

around or for the sov­er­eign plat­forms rather than against them. That is a struc­tural dif­fer­ence, not a dif­fer­ence of de­gree.

Elsewhere, startups build the platforms and the state pays. In the Gulf, the state builds the platforms, and is the dominant digital-health company.

The Gulf state oc­cu­pies four po­s­i­tions at once, and an entrant must know which one it is ad­dress­ing. It is the reg­u­lator, the payer, the builder of the rails and, through the sov­er­eign funds, the largest po­ten­tial ac­quirer. Be­neath that sit four buyer pools. Each has its own eco­nom­ics. The state buys for its pub­lic plat­forms, and the in­surers buy be­cause cover is now com­puls­ory. Em­ploy­ers fund group cover for staff and de­pend­ants, and the hos­pital sys­tems buy clin­ical soft­ware and ana­lyt­ics (Volge ana­lysis, 2026). The out-of-pocket con­sumer, which dom­in­ates In­dian di­gital health, is the weak­est of the five in the Gulf.

The build it­self is layered rather than mono­lithic. Saudi Ar­a­bia's Seha Vir­tual Hos­pital, re­launched in March 2025, sup­plies the clin­ical layer. The cit­izen front-ends, Se­h­haty, Mawid and the 937 ser­vice, handle ap­point­ments, re­cords and telemedi­cine for the pop­u­la­tion. In the UAE the health-in­form­a­tion ex­changes sup­ply the data layer with which telemedi­cine plat­forms are re­quired to in­teg­rate. Dis­tri­bu­tion and trust, the two most ex­pens­ive

Digital HealthState of Play14 •

things a con­sumer health busi­ness must buy else­where, are there­fore avail­able in the Gulf as pub­lic in­fra­struc­ture.

The de­pend­ency is the price of the ad­vant­age. It is a real one. Build­ing on gov­ern­ment rails means build­ing at the state's pace, and the rails dif­fer by coun­try, so a plat­form's roadmap be­comes partly a func­tion of a min­istry's. The stand­ing mit­ig­a­tion is di­ver­si­fic­a­tion of chan­nel rather than of mar­ket. An op­er­ator that earns the in­surer, the em­ployer and the hos­pital along­side the state is less ex­posed to any single pro­gramme's timetable than one whose whole dis­tri­bu­tion runs through a pub­lic plat­form.

Seha Virtual Hospital

The clearest proof of the sovereign-platform model is, by a verified world record, the largest virtual hospital on earth.

Saudi Ar­a­bia’s Seha Vir­tual Hos­pital is the flag­ship of the sov­er­eign-plat­form model and a genu­ine global first. Launched by the health min­istry in 2022, it was cer­ti­fied by Guin­ness World Re­cords in Oc­to­ber 2024 as the largest vir­tual health­care pro­vider in the world. The re­cord was audited. It is not a mar­ket­ing line. By the min­istry’s 2026 fig­ures it con­nects more than 242 hos­pit­als, spans dozens of spe­cial­ties and sub-spe­cial­ties, and car­ries an an­nual be­ne­fi­ciary ca­pa­city ap­proach­ing 600,000.

In 2025 it de­livered over 16 mil­lion vir­tual ap­point­ments and handled hun­dreds of thou­sands of com­plex clin­ical cases, grow­ing hard year on year.

Seha shows ex­actly what the top-down model can do that a private com­pany could not. No ven­ture-backed star­tup, capped by the scale ceil­ing, could have built a vir­tual hos­pital for an en­tire na­tion. The Saudi state simply built it, fun­ded it and de­ployed it across the king­dom by man­date. It hits the de­mand-side need squarely, stretch­ing scarce spe­cial­ists across dis­tance to a sick, under-served pop­u­la­tion, at a scale the private mar­ket’s eco­nom­ics would never have jus­ti­fied. Seha is the an­swer to the scale prob­lem from the only actor that can tran­scend it. That actor is the sov­er­eign, build­ing na­tional di­gital-health in­fra­struc­ture as a pub­lic good rather than a ven­ture. It is a warn­ing to private play­ers. The most valu­able tele­health plat­form in the king­dom be­longs to the state.

Key takeaways
  • Seha Vir­tual Hos­pital is the world’s largest: a veri­fied Guin­ness re­cord (Oct 2024).
  • 242+ hos­pit­als con­nec­ted, ~600k an­nual ca­pa­city, 16M+ vir­tual vis­its in 2025.
  • Only the sov­er­eign could build na­tional tele­health at a scale private eco­nom­ics would never jus­tify.

Seha Vir­tual Hos­pital con­nects 241 hos­pit­als and more than 1,400 health centres (Saudi Min­istry of Health, 9 Au­gust 2026), which su­per­sedes both the 242-hos­pital fig­ure car­ried in this series and the 224 hos­pit­als cited in earlier edi­tions. The cor­rec­tion is not merely arith­met­ical. The hos­pital

Digital HealthState of Play15 •

count alone un­der­states the plat­form. The primary-care layer of more than 1,400 health centres is where chronic-dis­ease man­age­ment at pop­u­la­tion scale ac­tu­ally reaches the pa­tient. The hos­pital was also re­launched in March 2025 on an ex­pan­ded ser­vice model. Both the reach and the primary-care layer be­neath it are wider than the earlier fig­ures im­plied.

The connected-hospital count is 241, not 242 or 224
hospitals connected
062.5125187.5250224Earlier editions242Carried in this series241Current, August 2026
Source: Saudi Ministry of Health, 9 August 2026

The re­por­ted out­comes are what make the plat­form mat­ter, not merely its size. Seha is cred­ited with a re­duc­tion of about 40 per cent in hos­pital stays and about 25 per cent in read­mis­sions, de­livered through ar­ti­fi­cial-in­tel­li­gence-as­sisted triage, re­mote con­sulta­tion and spe­cial­ist sup­port across the king­dom (Saudi Min­istry of Health, 2026). Those are the two meas­ures a payer cares about, which is why the plat­form is treated here as health-sys­tem in­fra­struc­ture rather than as a telemedi­cine ser­vice.

The com­pet­it­ive con­sequence for private op­er­at­ors is cor­res­pond­ingly nar­row. Basic vir­tual con­sulta­tion in Saudi Ar­a­bia is oc­cu­pied by a free, well-fun­ded pub­lic ser­vice with na­tional reach, so a private plat­form can­not com­pete on price or on breadth. What re­mains avail­able is spe­cialty depth, in­surer in­teg­ra­tion, con­veni­ence and demon­strated out­comes, and in many cases the bet­ter com­mer­cial po­s­i­tion is to sup­ply or in­teg­rate with the pub­lic plat­form rather than to con­test it.

Seha shows exactly what the top-down model can do that a private company could not.

The records and the exchanges

Beneath the apps, the Gulf has built national digital nervous systems, one per state, which is both the strength and the snare.

The deep­est layer of Gulf di­gital health is the na­tional elec­tronic health re­cord and health-in­form­a­tion ex­change. Here the sov­er­eign-plat­form model is most fully real­ised, state by state. The UAE runs Riay­ati, a fed­eral uni­fied med­ical re­cord link­ing over 3,000 fa­cil­it­ies. Along­side it sit Abu Dhabi’s Malaffi (the re­gion’s first health-in­form­a­tion ex­change, join­ing some 3,000 fa­cil­it­ies and 50,000 clini­cians) and Dubai’s Na­bidh (over 10

Digital HealthState of Play16 •

mil­lion re­cords and 53,000 pro­fes­sion­als). Saudi Ar­a­bia runs its na­tional ex­change through the PIF-owned plat­form com­pan­ies, and Qatar runs a na­tional re­cord on a global elec­tronic-health-re­cord sys­tem. Kuwait launched its con­sol­id­ated “Salem” app in late 2025, uni­fy­ing over 100 mil­lion re­cords. Oman and Bahrain run na­tional sys­tems too.

SystemMarketScale
Malaffi (HIE)Abu DhabiFirst HIE in MENA; ~3,000 facilities, 50k clinicians
Nabidh (HIE)Dubai10M+ records, 53k professionals
Riayati (EHR)UAE federal3,000+ facilities connected
Salem (app)Kuwait100M+ records unified (2025)

These ex­changes are genu­ine achieve­ments, na­tional di­gital nervous sys­tems most coun­tries lack, and they em­body the read’s ten­sion pre­cisely. Each is built at the scale of one na­tion, by the state, for the whole pop­u­la­tion. That is the sov­er­eign model work­ing as de­signed. But each is also na­tional, walled by data-loc­al­isa­tion rules, and in­com­pat­ible with its neigh­bours. The very in­fra­struc­ture that gives each Gulf state a na­tional-scale di­gital back­bone sim­ul­tan­eously hardens the bor­ders between the six mar­kets. The re­cords can­not cross them. The EHRs and HIEs are the clearest case of the Gulf doing di­gital health su­perbly within each state and, in the same stroke, mak­ing a uni­fied re­gional mar­ket harder to build.

Two fig­ures here need cor­rec­tion, and the cor­rec­ted ones strengthen the chapter's point. Riay­ati con­nects about 5,000 fa­cil­it­ies rather than the

3,000 stated, and NABIDH holds about 10.4 mil­lion re­cords across 1,888 con­nec­ted fa­cil­it­ies; taken to­gether, the UAE's three in­ter­con­nec­ted ex­changes make roughly 1.9 bil­lion re­cords ac­cess­ible (Malaffi, NABIDH and Riay­ati, 2026). In­teg­ra­tion with the rel­ev­ant ex­change is not op­tional: telemedi­cine plat­forms are re­quired to con­nect to NABIDH in Dubai, Malaffi in Abu Dhabi and Riay­ati na­tion­ally.

Facilities connected to each of the three UAE exchanges
facilities connected
01,2502,5003,7505,0005,000Riayati3,000Malaffi1,888NABIDH
Source: Malaffi, NABIDH and Riayati, 2026

Be­neath the ex­changes the en­ter­prise layer is con­cen­trated in two for­eign vendors. Or­acle Health, formerly Cerner, is the dom­in­ant hos­pital elec­tronic-med­ical-re­cord sys­tem across Saudi Ar­a­bia, the UAE, Qatar and Oman, while Epic holds the premium ter­tiary sites in­clud­ing Clev­e­land Clinic Abu Dhabi and Sidra Medi­cine (vendor and pro­vider dis­clos­ures,

Digital HealthState of Play17 •

2025 to 2026). The re­cord layer on which Gulf di­gital health runs is there­fore im­por­ted, and the ex­changes that ag­greg­ate it are sov­er­eign.

The op­por­tun­ity this leaves an entrant is spe­cific. The en­ter­prise re­cord is not con­test­able, but the in­teg­ra­tion layer above it is, as are the clinic and spe­cialty ap­plic­a­tions be­neath it and the ana­lyt­ics built on the pooled data. It is also the pre­con­di­tion for the re­gion's ar­ti­fi­cial-in­tel­li­gence am­bi­tions: pooled re­cords at na­tional scale are what a clin­ical model re­quires, and the Gulf has them in a form most health sys­tems do not. The same loc­al­isa­tion that walls the re­cords from each other is what made each na­tional pool co­her­ent enough to build on.

Sovereign capital and compute

The Gulf’s most extravagant advantage is the one least relevant to scale and most relevant to AI: near-limitless capital and compute.

If scale is the Gulf’s scarcity, cap­ital and com­pute are its abund­ance, and the fig­ures dwarf any­thing in the private health-tech mar­ket. Abu Dhabi’s G42, whose health arm helped form M42, took a $1.5 bil­lion in­vest­ment from Mi­crosoft in 2024. It also runs Condor Galaxy, among the most power­ful AI su­per­com­puter net­works on earth, on which its med­ical AI was trained. Saudi Ar­a­bia’s HUMAIN, backed by the Pub­lic In­vest­ment Fund, struck part­ner­ships in 2025 to de­ploy up to 600,000 ad­vanced AI

chips with one vendor alone, along­side multi-bil­lion-dol­lar deals with oth­ers. Health­care was named an early pri­or­ity. The UAE’s Star­gate pro­ject is build­ing a gigawatt-scale AI cam­pus.

The con­trast with private health-tech fund­ing is the whole point. The Gulf spends bil­lions on sov­er­eign com­pute while its en­tire health-tech ven­ture mar­ket raises tens of mil­lions. Cap­ital is not the con­straint here. This is the mir­ror image of India, where cap­ital is scarce and the pop­u­la­tion vast. So the Gulf’s ad­vant­age lies wherever cap­ital and com­pute mat­ter more than user scale, which is the AI layer. Sov­er­eign com­pute can­not man­u­fac­ture a large pop­u­la­tion, but it can train clin­ical AI to the highest stand­ard, and that is where the Gulf pours its abund­ance. The ad­vant­age is ex­tra­vag­ant, and aimed squarely at the one part of di­gital health where the num­ber of users mat­ters least.

Sov­er­eign cap­ital and ven­ture cap­ital in this sec­tor dif­fer by or­ders of mag­nitude, and the com­par­ison is the one that mat­ters. The Gulf's largest sov­er­eign funds com­mand roughly US$5 tril­lion in ag­greg­ate, and in­creas­ingly dir­ect it at health tech­no­logy as part of the di­ver­si­fic­a­tion agenda. Saudi Ar­a­bia's Pub­lic In­vest­ment Fund an­chors the build, and HUMAIN, its ar­ti­fi­cial-in­tel­li­gence ven­ture vehicle, is cap­it­al­ised at about US$10 bil­lion (sov­er­eign-fund and com­pany dis­clos­ures, 2025 to 2026). Dis­closed GCC health-tech­no­logy ven­ture in­vest­ment over the eight­een months to July 2026 was about US$148 mil­lion.

Digital HealthState of Play18 •

The funds do not merely in­vest, which is the dis­tinc­tion that mat­ters to an op­er­ator. Mubadala and G42 cre­ated M42 to fuse care de­liv­ery with ap­plied ar­ti­fi­cial in­tel­li­gence; the Pub­lic In­vest­ment Fund is build­ing the na­tional plat­form layer dir­ectly; and the Qatar In­vest­ment Au­thor­ity backs con­nec­ted-device and di­gital-health man­u­fac­tur­ers. The sov­er­eign funds are there­fore sim­ul­tan­eously the largest po­ten­tial part­ner, the route to the pub­lic rails and the most con­sequen­tial ac­quirer in the mar­ket, which makes align­ment with the sov­er­eign agenda a com­mer­cial ques­tion rather than a polit­ical one.

The cap­ital is also un­evenly dis­trib­uted within the re­gion. Saudi Ar­a­bia took roughly 64 per cent of MENA star­tup cap­ital in the first half of 2025. It led the third quarter with about US$3.2 bil­lion across 62 deals, ahead of the UAE at about US$1.2 bil­lion (MENA fund­ing track­ers, 2025). The money has con­cen­trated where the pop­u­la­tion and the plat­forms are. That is the same two-mar­ket con­cen­tra­tion which gov­erns every other vari­able in this read.

One sovereign vehicle is capitalised at three times a quarter of Saudi startup funding
US$ bn
02.557.51010HUMAIN vehicle3.2Saudi, Q3 20251.2UAE, Q3 2025
Source: sovereign-fund and company disclosures, 2025 to 2026

The data-localisation walls

The single regulatory fact that most entrenches the scale problem is the rule that health data must stay home.

The reg­u­lat­ory fea­ture that hardens the scale wall most dir­ectly is data loc­al­isa­tion. Each Gulf state re­quires health data to stay within its bor­ders. The UAE’s health-sec­tor ICT law man­dates that health data re­main in-coun­try, free zones in­cluded. Saudi Ar­a­bia’s data-gov­ernance re­gime and per­sonal-data-pro­tec­tion law im­pose their own res­id­ency and

Digital HealthState of Play19 •

trans­fer con­trols. The oth­ers fol­low suit. Health data, un­like most goods, can­not move freely across the bor­ders between the six mar­kets.

The con­sequence is struc­tural and de­cis­ive. A di­gital-health plat­form’s value comes from ag­greg­at­ing pa­tients and their data. Data loc­al­isa­tion means that ag­greg­a­tion can­not hap­pen across the re­gion, so no single plat­form can leg­ally pool the six mar­kets into one. A com­pany serving Saudi Ar­a­bia can­not simply ex­tend the same sys­tem, on the same data, into the UAE. It has to build and store sep­ar­ately in each, mul­tiply­ing cost and frag­ment­ing the very user base it set out to con­sol­id­ate. The loc­al­isa­tion rules are not an over­sight. They re­flect real sov­er­eignty and se­cur­ity con­cerns, but their ef­fect on di­gital health is to turn six small mar­kets into six sealed ones, fore­clos­ing the re­gional scale that might have off­set small na­tional pop­u­la­tions. Of all the con­straints in this read, data loc­al­isa­tion is the one that turns frag­ment­a­tion from a fric­tion into a wall.

En­force­ment, not draft­ing, is what has changed. The king­dom's Per­sonal Data Pro­tec­tion Law came into full ef­fect on 14 Septem­ber 2024 and is en­forced by the Saudi Data and Ar­ti­fi­cial In­tel­li­gence Au­thor­ity, which clas­si­fies health data at its most re­stric­ted tier along­side ge­netic and bio­met­ric data. By mid-Janu­ary 2026 the au­thor­ity's com­mit­tees had is­sued 48 de­cisions con­firm­ing breaches, most for pro­cessing without a law­ful basis, un­au­thor­ised dis­clos­ure or ab­sent safe­guards, and a con­trol­ler has as few as five days to re­spond once no­ti­fied (SDAIA, 2026). Loc­al­isa­tion in the Gulf is no longer a paper ob­lig­a­tion.

The ob­lig­a­tions are also deep­en­ing in scope. Law-firm com­ment­ary from the second quarter of 2026 re­ports that the au­thor­ity has moved to sec­tor audits in­clud­ing health­care. It also re­ports an ex­pect­a­tion of a data-pro­tec­tion im­pact as­sess­ment be­fore health data is pro­cessed, to­gether with a re­gistered data-pro­tec­tion of­ficer where pro­cessing is large-scale or sens­it­ive. These points rest on sec­ond­ary sources and war­rant veri­fic­a­tion against the au­thor­ity's own pub­lic­a­tions. Even so, the dir­ec­tion is con­sist­ent with the en­force­ment re­cord.

The ar­chi­tec­tural con­sequence is the one that bears on scale. A plat­form serving the re­gion must ar­chi­tect for loc­al­isa­tion from the out­set. Data is hos­ted and gov­erned sep­ar­ately under each of the three Gulf health-data re­gimes rather than con­sol­id­ated. That fore­closes the single re­gional data pool from which a plat­form's value would oth­er­wise com­pound. The cost is in­curred per mar­ket and re­covered against a small pop­u­la­tion, which is the mech­an­ism by which frag­ment­a­tion turns a mod­est mar­ket into sev­eral mar­ginal ones.

That clar­ity is a real asset most emer­ging mar­kets lack. Where In­dian e-phar­macy has run for years in a legal va­cuum, Gulf tele­health has ex­pli­cit li­cens­ing and defined stand­ards. More de­cis­ively, it has re­im­burse­ment. A pro­vider knows it can op­er­ate leg­ally and get paid. The catch, again, is the bor­der. Each of these sup­port­ive re­gimes is na­tional, so a pro­vider must ob­tain sep­ar­ate li­cences in each state, and the cer­tainty it en­joys at home does not ex­tend across the re­gion. The Gulf has built the legal

Digital HealthState of Play20 •

in­fra­struc­ture for di­gital health to thrive within each mar­ket (clear rules, a pay­ing payer, defined stand­ards) while leav­ing the bor­ders between mar­kets as hard as ever. It is the best reg­u­lat­ory en­vir­on­ment in the emer­ging world to op­er­ate a di­gital-health busi­ness in, and one of the hard­est to scale one across.

Telehealth, licensed and paid

Where the data rules fragment, the telehealth rules support: giving the Gulf the legal certainty most markets lack.

If data loc­al­isa­tion is the reg­u­lat­ory con­straint, tele­health li­cens­ing and re­im­burse­ment is the reg­u­lat­ory ad­vant­age, and the two to­gether cap­ture the Gulf’s reg­u­lat­ory char­ac­ter: sup­port­ive within each state, frag­men­ted across them. The Gulf states have built clear, mod­ern tele­health re­gimes. Dubai is­sues tele­health stand­ards and li­censes well over a hun­dred pro­viders; Abu Dhabi li­censes and re­im­burses telemedi­cine at a set fee; Saudi Ar­a­bia runs a na­tional telemedi­cine reg­u­la­tion and a ded­ic­ated unit of ex­cel­lence. Soft­ware-as-a-med­ical-device and even AI med­ical devices have spe­cific, bind­ing guid­ance, es­pe­cially in Saudi Ar­a­bia.

The clearest evid­ence that Gulf reg­u­la­tion sup­ports rather than ob­structs is the e-phar­macy seg­ment, where the con­trast with India is exact. The Saudi Food and Drug Au­thor­ity in­tro­duced man­dat­ory li­cens­ing and

pre­scrip­tion con­trols for on­line phar­ma­cies in 2023, so the seg­ment is reg­u­lated rather than op­er­at­ing in a va­cuum. It has grown ac­cord­ingly. GCC e-phar­macy is put at about US$2.37 bil­lion in 2024, rising to about US$9.44 bil­lion by 2033 at about 15.4 per cent. It is the most-used di­gital-health solu­tion in both Saudi Ar­a­bia and the UAE (IMARC and McKinsey, 2024 to 2026). Meas­ured re­ten­tion across di­gital-health app cat­egor­ies in the two mar­kets runs between 64 and 87 per cent.

Get­ting paid is like­wise defined rather than ne­go­ti­ated. Dubai's eClaimLink, re­in­forced by dir­ect­ive PD-05-2025, re­quires elec­tronic claims sub­mis­sion under set timelines with pen­al­ties at­tached, which con­verts re­im­burse­ment from a com­mer­cial ne­go­ti­ation into a tech­nical in­teg­ra­tion. A pro­vider that con­nects cor­rectly is paid; one that does not is pen­al­ised.

The li­cens­ing re­gimes re­main na­tional, how­ever, and in the UAE con­di­tional. Tele­health is li­censed state by state under pub­lished prac­tice rules. In the UAE a li­cence is con­tin­gent on in­teg­ra­tion with the rel­ev­ant health-in­form­a­tion ex­change. Legal cer­tainty is ac­quired per mar­ket rather than per re­gion. The Gulf is there­fore among the best reg­u­lated mar­kets in the emer­ging world in which to op­er­ate a di­gital-health busi­ness, and among the most ex­pens­ive in which to as­semble one across bor­ders.

AI es­capes the pop­u­la­tion cap that holds con­sumer health-tech down. A clin­ical model trained on Gulf com­pute can serve a small na­tional pop­u­la­tion su­perbly and, in prin­ciple, be ex­por­ted far bey­ond the re­gion, clear­ing the scale ceil­ing en­tirely. AI also at­tacks the Gulf’s real de­mand-side

Digital HealthState of Play21 •

con­straint. That con­straint is not a short­age of pa­tients but a short­age of clini­cians, which AI mul­ti­plies. And it plays to the Gulf’s strengths of cap­ital and com­pute, to its data and to the sov­er­eign au­thor­ity to de­ploy na­tion­ally, rather than to its weak­ness in scale. The Gulf may never grow a con­sumer health-tech cham­pion the size of an In­dian or Amer­ican one, but it can plaus­ibly lead the world in sov­er­eign clin­ical AI. That is the layer where the num­ber of users mat­ters least, and it is where the everything-but-scale prob­lem is fi­nally solved.

AI: where the Gulf leads

There is one layer of digital health where scale of users matters less than scale of compute, and there, the Gulf leads.

The one part of di­gital health where the Gulf’s ad­vant­ages line up per­fectly with the op­por­tun­ity is ar­ti­fi­cial in­tel­li­gence. AI runs on scale of com­pute and cap­ital, which the Gulf has in abund­ance, rather than scale of users, which it lacks. The re­gion is build­ing genu­ine AI lead­er­ship in health. Abu Dhabi’s M42 trained its Med42 clin­ical large lan­guage model on sov­er­eign su­per­com­puters, re­port­ing per­form­ance com­pet­it­ive with the strongest gen­eral mod­els on med­ical bench­marks. Saudi Ar­a­bia’s Seha Vir­tual Hos­pital de­ploys AI for ima­ging pre-reads, breast-can­cer and dia­betic-ret­ino­pathy screen­ing, and has val­id­ated smart­phone-based

vital-signs read­ing. The na­tional data-and-AI au­thor­ity has ear­marked tens of bil­lions for AI, with health a pri­or­ity.

The case for Gulf lead­er­ship in clin­ical ar­ti­fi­cial in­tel­li­gence rests on three in­puts the re­gion holds. The first is pooled data. Roughly 1.9 bil­lion re­cords are ac­cess­ible across the UAE's three ex­changes, and the Saudi na­tional plat­form layer ag­greg­ates at king­dom scale. That is the pre­con­di­tion a clin­ical model re­quires, and most health sys­tems have not met it. The second is com­pute and cap­ital, with HUMAIN cap­it­al­ised at about US$10 bil­lion and sov­er­eign funds of roughly US$5 tril­lion be­hind the wider build. The third is gov­ernance. The Gulf states have framed ar­ti­fi­cial-in­tel­li­gence-in-health rules ahead of the de­ploy­ment curve rather than be­hind it.

De­ploy­ment is already meas­ur­able in the pub­lic sys­tem. Seha Vir­tual Hos­pital op­er­ates ar­ti­fi­cial-in­tel­li­gence-as­sisted triage with re­por­ted ac­cur­acy of up to 95 per cent, along­side re­mote con­sulta­tion and spe­cial­ist sup­port. The ap­plied stacks of M42 and G42 sit be­hind the Abu Dhabi data land­scape (Saudi Min­istry of Health and com­pany dis­clos­ures, 2026). The ven­ture layer is form­ing in the same dir­ec­tion, if thinly. Nux­era AI raised a US$2.5 mil­lion pre-seed round backed by the San­abil ven­ture stu­dio.

The con­straint on this layer is dif­fer­ent in kind from the con­straint on the rest of the mar­ket. Clin­ical ar­ti­fi­cial in­tel­li­gence is gated by tal­ent, data ac­cess, clin­ical val­id­a­tion and gov­ernance rather than by user num­bers or man­u­fac­tur­ing, which is pre­cisely why the Gulf has chosen it. The moat is data ac­cess and val­id­ated clin­ical per­form­ance, and both are avail­able to a com­pany that builds with the sov­er­eign rather than around it.

Digital HealthState of Play22 •

The part in brief

  1. 01The flagship platform links 241 hospitals and over 1,400 health centres, and is credited with roughly 40 per cent fewer hospital stays.
  2. 02Three UAE exchanges put roughly 1.9 billion records within reach, NABIDH alone holding about 10.4 million across 1,888 connected facilities.
  3. 03Sovereign money works on another scale: HUMAIN carries about US$10 billion against health-technology venture investment of about US$148 million.
  4. 04Capital follows the same concentration: the kingdom drew about 64 per cent of first-half MENA startup funding in 2025 and led the third quarter on 62 deals.
  5. 05Enforcement has hardened, with 48 breach decisions confirmed by mid-January 2026, while triage on the public platform reports accuracy up to 95 per cent.
Digital HealthState of Play23 •
The Machine

Elsewhere, startups build the platforms and the state pays. In the Gulf, the state builds the platforms, and is the dominant digital-health company.

03

The Players

The super-apps, the champions, and the funding gap that proves the thesis.

The sovereign super-apps

The Gulf’s biggest consumer health platforms are not startups. They are government apps, pushed to whole nations at once.

The largest con­sumer-fa­cing di­gital-health plat­forms in the Gulf are state-built super-apps, and Saudi Ar­a­bia’s Se­h­haty is the ex­em­plar. Built for the health min­istry, Se­h­haty passed 31 mil­lion users and de­livered over 51 mil­lion vir­tual con­sulta­tions and ap­point­ments in 2024. Dozens of ser­vices are fol­ded into a single na­tional app, among them ap­point­ments and re­cords, pre­scrip­tions and vir­tual vis­its, and even a Google-powered AI health coach. Its pen­et­ra­tion, in a coun­try of 35 mil­lion, is a level no private app could reach com­mer­cially. It got there be­cause the state de­ployed it to the whole pop­u­la­tion.

The super-apps re­veal the struc­tural truth of Gulf di­gital health. The user num­bers a ven­ture-backed star­tup dreams of, tens of mil­lions, are cap­tured not by a star­tup but by a gov­ern­ment plat­form. The plat­form is handed to cit­izens as a pub­lic ser­vice and paid for from the state budget. That both proves the de­mand (Saudis clearly want di­gital health, and use it heav­ily) and fore­closes the private op­por­tun­ity (a star­tup can­not com­pete with a free, man­dated na­tional super-app). The sov­er­eign super-app is the scale solu­tion and the private-mar­ket prob­lem in one. It proves the Gulf can reach di­gital-health scale, but only through the state, and in doing so it

The state app reaches most of the population it was built for
million, 2024
01530456051Virtual consultations35Saudi population31Sehhaty users
Source: company disclosures, 2023 to 2026

oc­cu­pies the con­sumer space a private com­pany would oth­er­wise con­test. For com­mer­cial play­ers, the les­son is to in­teg­rate with or build for the super-app, not against it.

The super-app layer is broader than a single ap­plic­a­tion, and its breadth is what fore­closes the private con­sumer po­s­i­tion. Saudi Ar­a­bia fronts its health sys­tem with Se­h­haty, Mawid and the 937 ser­vice, which between them handle ap­point­ments, re­cords and telemedi­cine for the pop­u­la­tion. In the UAE the cit­izen-fa­cing layer is bound to the ex­changes with which any telemedi­cine pro­vider must in­teg­rate. These are state-built and state-run, free at the point of use. They are the de­fault chan­nel against which a private ser­vice is com­pared.

Digital HealthState of Play24 •

The private layer that has grown along­side them is in­struct­ive in its pro­por­tions. Cura, one of the lar­ger Saudi private vir­tual-care plat­forms, re­ports more than 350,000 users and more than 4,500 doc­tors. Alt­ibbi, the lead­ing health ap­plic­a­tion in the wider MENA re­gion, has raised about US$50 mil­lion in­clud­ing a US$44 mil­lion Series B in 2023 (com­pany dis­clos­ures, 2023 to 2026). These are re­spect­able busi­nesses meas­ured against their cap­ital. They are small meas­ured against a na­tional ap­plic­a­tion dis­trib­uted by man­date.

The in­struc­tion that fol­lows is po­s­i­tional, not com­pet­it­ive. A private op­er­ator should spe­cial­ise, tak­ing a spe­ci­al­ity or a pop­u­la­tion the pub­lic ser­vice does not serve well, in­teg­rate with the pub­lic rails for dis­tri­bu­tion and in­ter­op­er­ab­il­ity, and mon­et­ise through the in­surer rather than the con­sumer. The pub­lic plat­forms lower the cost of dis­tri­bu­tion and of trust for any­one will­ing to build on them, and they raise it to a pro­hib­it­ive level for any­one in­tend­ing to re­place them. The super-apps are bet­ter read as in­fra­struc­ture to be used than as com­pet­it­ors to be dis­placed.

For commercial players, the lesson is to integrate with or build for the super-app, not against it.

M42 mat­ters be­cause it shows the Gulf play­ing to its strengths rather than fight­ing its con­straints. It does not try to win a con­sumer-scale race it can­not win. It builds at the AI and en­ter­prise layer, where the Gulf’s cap­ital,

com­pute and data lead, and it ex­pands in­ter­na­tion­ally to es­cape the do­mestic scale ceil­ing. Med42 can serve the UAE’s small pop­u­la­tion and, as an ex­port­able model, reach far bey­ond it. That is the one path that tran­scends the 61-mil­lion wall. M42 is proof the Gulf can build a di­gital-health asset of genu­ine in­ter­na­tional stand­ing, provided it builds the kind that scales by com­pute and ex­port rather than by do­mestic users. It is the everything-but-scale thesis turned into a strategy: lead in AI, ex­pand abroad, and let the sov­er­eign cap­ital do what user num­bers can­not.

M42 and Med42: the AI champion

The Gulf’s most credible claim to digital-health leadership is a sovereign-backed fusion of healthcare and frontier AI.

M42 is the Gulf’s flag­ship di­gital-health cham­pion, and it em­bod­ies the read’s res­ol­u­tion: build where cap­ital and com­pute mat­ter more than user scale. Formed in 2023 from the mer­ger of G42 Health­care and Mubadala Health, M42 em­ploys more than 20,000 people and runs over 450 fa­cil­it­ies across 26 coun­tries, in­ter­na­tional already, be­cause the Gulf mar­ket alone is too small to hold its am­bi­tion. Its dis­tinct­ive asset is Med42, an open clin­ical large lan­guage model trained on G42’s sov­er­eign

Digital HealthState of Play25 •

su­per­com­puters, which M42 re­ports per­forms com­pet­it­ively with the strongest gen­eral-pur­pose mod­els on med­ical ex­am­in­a­tions.

Key takeaways
  • M42 (G42 Health + Mubadala): 20,000+ staff, 450+ fa­cil­it­ies, 26 coun­tries: in­ter­na­tional by ne­ces­sity.
  • Med42, trained on sov­er­eign com­pute, com­petes with the strongest med­ical AI mod­els.
  • The strategy: lead in AI, ex­port abroad: the one path past the do­mestic scale ceil­ing.

M42's sig­ni­fic­ance is struc­tural as much as clin­ical. Mubadala and G42 cre­ated the com­pany ex­pressly to fuse care de­liv­ery with ap­plied ar­ti­fi­cial in­tel­li­gence, which places a single sov­er­eign-backed en­tity on both sides of the re­la­tion­ship that nor­mally sep­ar­ates a health sys­tem from its tech­no­logy sup­plier. The same en­tity also sits on the data layer: Malaffi, the Abu Dhabi health-in­form­a­tion ex­change, is op­er­ated through M42 and Abu Dhabi Health Data Ser­vices (com­pany and au­thor­ity dis­clos­ures, 2026). De­liv­ery, data and model de­vel­op­ment are held within one sov­er­eign-backed group.

That in­teg­ra­tion is the source of the ad­vant­age. The moat in clin­ical ar­ti­fi­cial in­tel­li­gence is data ac­cess and val­id­ated clin­ical per­form­ance rather than user scale, and an en­tity that op­er­ates the ex­change, the hos­pit­als and the model de­vel­op­ment has priv­ileged ac­cess to both. No

in­de­pend­ently fin­anced com­pany in a mar­ket of this size could as­semble the same po­s­i­tion, which is why the Gulf's cred­ible claim to lead­er­ship in this layer is a sov­er­eign claim rather than a ven­ture one.

The lim­it­a­tion is the coun­ter­part of the ad­vant­age. A cham­pion as­sembled this way is not a tem­plate a private op­er­ator can fol­low; it is a coun­ter­party a private op­er­ator must plan around. For most com­mer­cial play­ers the real­istic re­la­tion­ship with M42 and its peers is as a sup­plier, an in­teg­ra­tion part­ner or an ac­quis­i­tion can­did­ate, the sov­er­eign funds being the most con­sequen­tial ac­quirers in the mar­ket. The strategy the chapter de­scribes is avail­able in full only to those the sov­er­eign builds.

PureHealth: scale by acquisition abroad

The region’s largest health group solved the scale problem the only way the Gulf can: by buying it overseas.

PureHealth, the Middle East’s largest health­care group, of­fers the second route past the scale ceil­ing. The route is to buy it abroad. Backed by Abu Dhabi’s ADQ, PureHealth raised about $986 mil­lion in its Decem­ber 2023 IPO and pos­ted FY2024 rev­enue of around AED 25.8 bil­lion, up 58%, net profit up 78%. It grew not by sat­ur­at­ing the small Gulf mar­ket but by buy­ing in­ter­na­tion­ally. The UK’s Circle Health was ac­quired

Digital HealthState of Play26 •

for about $1.2 bil­lion, along with a ma­jor­ity of a major Greek hos­pital group. The res­ult is a mul­tina­tional plat­form across pro­vi­sion, dia­gnostics, in­sur­ance and di­gital health.

PureHealth con­firms the thesis from the com­mer­cial side. A Gulf health cham­pion can­not reach world scale within the Gulf, so the suc­cess­ful ones reach out­ward. M42 runs across 26 coun­tries, and PureHealth has gone into Bri­tain and Greece and holds a US foot­print. The do­mestic mar­ket sup­plies the sov­er­eign cap­ital and the home base. The scale comes from abroad. For an in­vestor, this is the de­fin­ing pat­tern of Gulf health plat­forms. They are sov­er­eign-fun­ded vehicles that use Gulf cap­ital to ac­quire in­ter­na­tional scale, not or­gan­ic­ally-grown busi­nesses scal­ing a do­mestic mar­ket. PureHealth demon­strates what Gulf cap­ital can build. It also ad­mits quietly what it can­not build at home, which is scale. The growth is real. It just hap­pens over­seas, be­cause that is where the people are.

The pat­tern PureHealth il­lus­trates runs through the re­gion's deal flow more broadly, and it is not con­fined to out­bound ac­quis­i­tion. Much of the largest activ­ity in Gulf health is stra­tegic or sov­er­eign-linked rather than clas­sic early-stage ven­ture. The biggest trans­ac­tions are struc­tured to buy dis­tri­bu­tion and in­stalled base rather than to build it. Aster DM's myAster joint ven­ture with Al Hokair, cap­it­al­ised at about US$250 mil­lion to open 186 phar­ma­cies across Saudi Ar­a­bia, is the in­bound ver­sion of the same logic. Scale is ac­quired through a part­ner's foot­print rather than grown through cus­tomer ac­quis­i­tion (com­pany dis­clos­ures, 2025 to 2026).

The reason the logic re­curs is the arith­metic of the do­mestic mar­ket. Where the ad­dress­able pop­u­la­tion in any one state is small and ac­quis­i­tion cost is high, the cheapest route to a large user base is to pur­chase one that already ex­ists, whether abroad or through a local in­cum­bent's foot­print. Or­ganic con­sumer growth is the most ex­pens­ive path avail­able in this mar­ket and the least likely to reach ven­ture-scale re­turns.

For an in­vestor the im­plic­a­tion is a test rather than a pref­er­ence. A Gulf health plat­form's growth should be ex­amined for its source. The source may be ag­greg­a­tion across the six states, ac­quis­i­tion of an ex­ist­ing foot­print at home, or ac­quis­i­tion abroad. Only the first is genu­inely re­gional, and only the first com­pounds with the mar­ket's own growth. Scale bought over­seas di­ver­si­fies the busi­ness away from the Gulf con­straint rather than solv­ing it.

The thin startup layer

For all the wealth and ambition, the Gulf’s private health-tech startup scene is strikingly thin, and stale.

The most telling evid­ence for the scale thesis is what is miss­ing. There is no thriv­ing private health-tech star­tup eco­sys­tem. For all the payer ad­vant­age, the cap­ital and the de­mand, the Gulf has pro­duced re­l­at­ively few scaled private di­gital-health com­pan­ies, and the land­mark fund­ing

Digital HealthState of Play27 •

rounds are con­spicu­ously dated. The re­gion’s best-known telemedi­cine star­tup raised its major round in 2022. Other prom­in­ent names in book­ing and dia­gnostics, and in in­sur­ance tech­no­logy, raised their last major rounds between 2020 and 2022, and a sweep for fresh 2024–2026 rounds turned up little. The private layer ex­ists, but it is thin and quiet.

The reason is the scale ceil­ing work­ing ex­actly as the thesis pre­dicts. A health-tech star­tup needs a large ad­dress­able mar­ket to jus­tify ven­ture in­vest­ment and grow into a valu­able com­pany; the Gulf of­fers a small one, frag­men­ted across six states, with the most at­tract­ive con­sumer space already oc­cu­pied by free gov­ern­ment super-apps. So private founders struggle to build the user base that pulls in fol­low-on cap­ital, and in­vestors struggle to see the exits that jus­tify the risk. The star­tups that do suc­ceed tend to serve en­ter­prise or in­surer cus­tom­ers (where the payer pays) or to ex­pand abroad early. The thin, stale star­tup layer is not a fail­ure of tal­ent or cap­ital; it is the pre­dict­able con­sequence of a mar­ket that has everything ex­cept the scale a star­tup needs. It is the thesis, vis­ible in an ab­sence.

The thin­ness is meas­ur­able, and re­cently so. Dis­closed GCC health-tech­no­logy in­vest­ment amoun­ted to about US$148 mil­lion across 32 star­tups between Janu­ary 2025 and July 2026, with 21 rounds com­pleted in 2025 and 11 in the first half of 2026. Saudi Ar­a­bia ac­coun­ted for 17 of the com­pan­ies and the UAE for 11 (PitchBook, via WHX Tech, 2026). This is a nar­rower scope than the MENA totals usu­ally quoted. It is the fig­ure that cor­res­ponds to the ques­tion being asked here.

Selected GCC and MENA digital-health rounds
US$ m raised
Vezeeta, cumulative63Altibbi, Series B 202344Klaim, Series A 202526Okadoc, cumulative22.3Alma Health, Series A10MedIQ, Series A6Nuxera AI, pre-seed2.5
Source: Wamda, Arab News and company disclosures, 2023 to 2026

The in­di­vidual rounds show where the few suc­cesses sit. Alt­ibbi has raised about US$50 mil­lion in­clud­ing a US$44 mil­lion Series B in 2023. It is the re­gion's clearest can­did­ate to reach uni­corn stand­ing, pre­cisely be­cause it ag­greg­ates de­mand across sev­eral mar­kets. Vezeeta has raised more than US$63 mil­lion, mov­ing from book­ing into tele­con­sulta­tion and phar­macy soft­ware. Klaim raised a US$26 mil­lion Series A in 2025 on the claims rail. Okadoc has raised about US$22.3 mil­lion and is ex­tend­ing from the UAE into Saudi Ar­a­bia. Alma Health raised a US$10 mil­lion Series A in vir­tual chronic care. MedIQ's US$6 mil­lion Series A ranks among the largest Saudi health-tech­no­logy rounds to date.

The com­pos­i­tion of that list is the ar­gu­ment. The bet­ter-fun­ded com­pan­ies are re­gional ag­greg­at­ors, claims and in­surer plays, or chronic-care

Digital HealthState of Play28 •

busi­nesses with a re­im­burs­ing payer be­hind them. The in­sti­tu­tional scaf­fold­ing is matur­ing in the same dir­ec­tion, through Hub71+ Life Sci­ences in Abu Dhabi and the San­abil ven­ture stu­dio in Saudi Ar­a­bia, but it is build­ing a spe­cial­ist layer rather than a con­sumer one.

The funding gap

One pair of numbers captures the entire read: billions for sovereign compute, tens of millions for health-tech startups.

If a single com­par­ison proves the everything-but-scale thesis, it is the fund­ing gap. In 2025 the en­tire GCC health-tech ven­ture mar­ket raised about $36.2 mil­lion across a dozen rounds. That was a real year-on-year in­crease, but a tiny fig­ure in ab­so­lute terms, against a cu­mu­lat­ive all-time total of only some $341 mil­lion across 125 com­pan­ies. In the same win­dow, the Gulf’s sov­er­eign funds were com­mit­ting bil­lions to AI com­pute and health plat­forms. The re­gion de­ploys bil­lions through the state. It raises tens of mil­lions through ven­ture cap­ital.

The gap is not a con­tra­dic­tion. It is the struc­ture of the mar­ket. Ven­ture cap­ital flows to where scale prom­ises re­turns, and the Gulf’s small, frag­men­ted pop­u­la­tions cap the scale a star­tup can reach. So private health-tech fund­ing stays small, while sov­er­eign cap­ital, which needs no ven­ture-scale user eco­nom­ics, flows freely into state-built plat­forms and

com­pute. (One cau­tion on the num­bers: much-quoted MENA health-tech totals of hun­dreds of mil­lions, or all-sec­tor totals in the bil­lions, are wider geo­graph­ies and often debt-skewed; the clean GCC-only health-tech ven­ture fig­ure is the $36 mil­lion.) The fund­ing gap is the read in a single stat­istic. It is a mar­ket awash in sov­er­eign cap­ital and starved of ven­ture cap­ital, be­cause the first does not need scale and the second can­not find it. Money is not the Gulf’s di­gital-health prob­lem. The ab­sence of the scale that would at­tract private money is.

The gap is wider still once the sov­er­eign side is quan­ti­fied on a com­par­able basis. Dis­closed GCC health-tech­no­logy ven­ture in­vest­ment was about US$148 mil­lion across 32 star­tups between Janu­ary 2025 and July 2026. Against that sits HUMAIN, a single Saudi ar­ti­fi­cial-in­tel­li­gence ven­ture vehicle, cap­it­al­ised at about US$10 bil­lion, and sov­er­eign funds hold­ing roughly US$5 tril­lion in ag­greg­ate (PitchBook via WHX Tech, and sov­er­eign-fund dis­clos­ures, 2026). A single stra­tegic health trans­ac­tion, Aster DM's US$250 mil­lion phar­macy joint ven­ture, ex­ceeds the re­gion's en­tire dis­closed health-tech­no­logy ven­ture flow over eight­een months.

The com­par­ison must be made on a stated scope, be­cause the com­monly quoted totals are not com­par­able. MENA star­tups across all sec­tors raised about US$2.1 bil­lion in the first half of 2025, up about 134 per cent year on year, of which Saudi Ar­a­bia took roughly 64 per cent. Those fig­ures cover every sec­tor and a wider geo­graphy than the Gulf, and they are routinely mis­taken for health-tech­no­logy fund­ing. The clean GCC

Digital HealthState of Play29 •
Sovereign commitment against disclosed health-tech venture
US$ m
02,5005,0007,50010,00010,000HUMAIN AI vehicle250Aster DM pharmacy JV148GCC health-tech, Jan 2025 toJul 2026
Source: PitchBook via WHX Tech and company disclosures, 2026

health-tech­no­logy series is the US$148 mil­lion fig­ure, and it is the only one that an­swers the ques­tion.

Disclosed venture funding for GCC health technology, on three scopes
US$ m
All time, 125 companies341Jan 2025 to Jul 2026148Calendar 202536.2
Source: PitchBook via WHX Tech

The struc­tural read­ing stands un­changed by the re­vi­sion. Ven­ture cap­ital is ab­sent not be­cause the Gulf lacks money but be­cause the scale that

pro­duces ven­ture re­turns is not avail­able do­mest­ic­ally. Sov­er­eign cap­ital is ap­praised against na­tional ob­ject­ives rather than against user eco­nom­ics, and it flows freely into plat­forms, com­pute and stra­tegic ac­quis­i­tion. The two num­bers are not in ten­sion. They are the same con­straint ob­served from two sides.

The gap is wider still once the sovereign side is quantified on a comparable basis.

The crowding-out question

When the state builds the platforms and funds the ventures, what room is left for a private company?

A sharper ver­sion of the scale prob­lem is the crowding-out ques­tion. Does the sov­er­eign model leave room for a private di­gital-health sec­tor at all? The dy­namic is real, and in­creas­ingly noted. The state builds the dom­in­ant con­sumer plat­forms (the super-apps) and owns the most valu­able as­sets (the vir­tual hos­pital, the re­cords). Through the sov­er­eign funds it even in­cub­ates ven­tures dir­ectly. That has given rise to what ana­lysts have called the “GCC sov­er­eign star­tup,” a com­pany foun­ded and fun­ded by a state in­vestor rather than in­de­pend­ent ven­ture cap­ital. In a

Digital HealthState of Play30 •

mar­ket this small, a private founder com­petes against the scale ceil­ing and against the state it­self.

The hon­est read holds two truths in ten­sion. The sov­er­eign model is genu­inely ef­fect­ive. It has built na­tional plat­forms of the first rank and AI cap­ab­il­ity that no private mar­ket this size could have pro­duced, and it chan­nels pa­tient cap­ital into long-term in­fra­struc­ture. It also nar­rows the private op­por­tun­ity, be­cause the con­sumer space is oc­cu­pied, the best as­sets are state-owned, and in­de­pend­ent ven­ture cap­ital is scarce partly be­cause the state is both com­pet­itor and the main source of cap­ital. The likely equi­lib­rium is a mar­ket where the sov­er­eign builds the plat­forms and the AI, and private play­ers find their room at the edges, serving en­ter­prise and in­surer cus­tom­ers, sup­ply­ing the sov­er­eign plat­forms, or ex­pand­ing abroad. The crowding-out ques­tion has no tra­gic an­swer, but it has a de­fin­ing one. In the Gulf, the private di­gital-health op­por­tun­ity is shaped, and bounded, by the sov­er­eign that dom­in­ates the space.

The crowding-out dy­namic can be spe­cified rather than merely as­ser­ted, and it op­er­ates through three chan­nels. The first is the product chan­nel. Basic vir­tual con­sulta­tion is sup­plied free at na­tional scale by the pub­lic plat­form, so the most ac­cess­ible con­sumer pro­pos­i­tion is oc­cu­pied be­fore an entrant ar­rives. The second is the data chan­nel. The ex­changes are state-run and in­teg­ra­tion with them is man­dat­ory, so the pooled data on which a plat­form's ana­lyt­ics would com­pound is held by the sov­er­eign rather than by the com­pany. The third is the cap­ital chan­nel, where the

sov­er­eign funds are at once the largest in­vestor, the route to the rails and the most con­sequen­tial ac­quirer.

The third chan­nel is the one that most changes the char­ac­ter of the private layer. Where a ven­ture is foun­ded in­side a sov­er­eign pro­gramme, as with Nux­era AI's pre-seed round backed by the San­abil ven­ture stu­dio, the dis­tinc­tion between a star­tup and a state ini­ti­at­ive be­comes a mat­ter of struc­ture rather than of sub­stance. In­de­pend­ent cap­ital is scarce partly be­cause the state is both the com­pet­itor and the prin­cipal source of funds.

The equi­lib­rium this pro­duces is work­able rather than closed, and the stand­ing mit­ig­a­tions are known. An op­er­ator spe­cial­ises in­stead of com­pet­ing on breadth, and in­teg­rates with the pub­lic plat­forms in­stead of against them. It di­ver­si­fies chan­nel across the in­surer, the em­ployer and the hos­pital, so that no single pro­gramme's timetable gov­erns its rev­enue. It also part­ners with sov­er­eign and aca­demic in­sti­tu­tions on the tal­ent it can­not oth­er­wise re­cruit. The private op­por­tun­ity in Gulf di­gital health is genu­ine, and it is defined by the sov­er­eign rather than by the mar­ket.

Saudi Ar­a­bia’s ad­vant­age is that its lar­ger pop­u­la­tion makes the sov­er­eign-plat­form model most vi­able. A na­tional super-app with 31 mil­lion users is mean­ing­ful scale even by global stand­ards. Its strategy is the most am­bi­tious and best-re­sourced in the Gulf, pair­ing the plat­form build with the sov­er­eign-com­pute in­vest­ments (HUMAIN and its AI part­ner­ships) that aim to lead in clin­ical AI. The lim­it­a­tion is the one the whole read de­scribes. Even 35 mil­lion is mod­est glob­ally, the private star­tup layer stays

Digital HealthState of Play31 •

thin be­neath the state plat­forms, and the king­dom’s di­gital-health value con­cen­trates in gov­ern­ment-owned as­sets. Saudi Ar­a­bia is where the sov­er­eign model works best, pre­cisely be­cause it is where the Gulf comes closest to scale, and it is still a mar­ket the state, not the private sec­tor, dom­in­ates.

Saudi Arabia: the platform state

The largest Gulf market is also the most fully realised expression of the sovereign-platform model.

Saudi Ar­a­bia is the Gulf’s largest di­gital-health mar­ket and the purest case of the plat­form state. With 35 mil­lion people, more than half the re­gion’s pop­u­la­tion, it has the closest thing the Gulf of­fers to genu­ine na­tional scale. It has used the state to build plat­forms across the whole stack. Seha Vir­tual Hos­pital sits at the clin­ical layer and Se­h­haty at the con­sumer layer, with the PIF-owned plat­form com­pan­ies run­ning re­cords and ex­changes and the data-and-AI au­thor­ity fund­ing clin­ical AI. Vis­ion 2030’s health trans­form­a­tion, the privat­isa­tion of hos­pit­als into the Health Hold­ing Com­pany, and a na­tional in­sur­ance pro­gramme tar­geted for 2026 com­plete a co­ordin­ated, state-driven build.

Two cor­rec­tions sharpen the king­dom's po­s­i­tion, and both strengthen it. The first is the payer. Saudi Ar­a­bia already re­quires Coun­cil of Health

In­sur­ance-com­pli­ant cover from every private em­ployer, so the man­date is op­er­at­ive rather than, as stated here, a pro­gramme tar­geted for 2026. The second is the mar­ket basis. Saudi di­gital health is put at about US$4.4 bil­lion in 2025, rising to about US$18 bil­lion by 2032 at about 22 per cent a year. That makes the king­dom roughly seven tenths of the re­gional mar­ket on the re-based GCC total of about US$6.28 bil­lion for the same year (Mar­ket Re­search Fu­ture and na­tional series, 2026).

Saudi Arabia is seven tenths of the regional market and quadruples it by 2032
US$ bn
051015204.4Saudi, 20256.3GCC, 202518Saudi, 2032
Source: Market Research Future and national series, 2026

That con­cen­tra­tion ex­tends to cap­ital as well as to de­mand. Saudi Ar­a­bia took roughly 64 per cent of MENA star­tup cap­ital in the first half of 2025 and led the third quarter with about US$3.2 bil­lion across 62 deals. Saudi com­pan­ies made up 17 of the 32 GCC health-tech­no­logy com­pan­ies fun­ded between Janu­ary 2025 and July 2026. HUMAIN, the Pub­lic In­vest­ment

Digital HealthState of Play32 •

Fund's ar­ti­fi­cial-in­tel­li­gence ven­ture vehicle cap­it­al­ised at about US$10 bil­lion, sits be­hind the com­pute layer, while the San­abil ven­ture stu­dio sup­plies the thin ven­ture layer above it.

The kingdom commits more to one AI vehicle than its digital-health market is worth
US$ bn
02.557.51010HUMAIN vehicle4.4Digital health, 20253.2Q3 2025 funding
Source: Market Research Future and national series, 2026

The king­dom is there­fore the only Gulf mar­ket in which the sov­er­eign model op­er­ates at some­thing ap­proach­ing genu­ine na­tional scale, and it is also the mar­ket in which the state's share of the avail­able value is highest. The clin­ical layer, the cit­izen front-ends, the re­cords and the com­pute are all state-held. A private op­er­ator's po­s­i­tion in Saudi Ar­a­bia is ac­cord­ingly defined by what it can sup­ply to that land­scape, or by the spe­ci­al­it­ies and pop­u­la­tions the state serves least well.

The UAE’s bet is that con­nectiv­ity, cap­ital, reg­u­lat­ory soph­ist­ic­a­tion and open­ness can make it the place where Gulf di­gital health is fun­ded, built

and ex­por­ted, even with a small pop­u­la­tion at home. It leads the re­gion in health-in­form­a­tion ex­change, in AI, and in at­tract­ing and de­ploy­ing sov­er­eign and for­eign cap­ital. The strategy is hon­est about the ceil­ing. Rather than pre­tend 11 mil­lion is a large mar­ket, it aims to be the node through which the re­gion’s di­gital-health cap­ital and cap­ab­il­ity flow out­ward. The lim­it­a­tion is that a hub strategy leans on the AI and en­ter­prise lay­ers, where the UAE genu­inely leads, not on con­sumer scale, which it lacks as much as any­one. The UAE has chosen the smartest avail­able an­swer to everything-but-scale. The ceil­ing is not fought but built above, in AI, in cap­ital, in in­ter­na­tional reach.

The UAE: the hub

Too small to scale at home, the UAE built the model that escapes the ceiling: become the regional and AI hub.

The UAE, with about 11 mil­lion people, can­not chase scale through its do­mestic pop­u­la­tion, so it has built the Gulf’s most de­lib­er­ate strategy for tran­scend­ing the ceil­ing: be­come the hub. Abu Dhabi’s health groups, M42, PureHealth and the wider G42-and-Mubadala con­stel­la­tion, are ex­pli­citly in­ter­na­tional, ex­pand­ing across dozens of coun­tries and ac­quir­ing abroad. The emir­ate has cast it­self as the re­gional centre for health AI (Med42, sov­er­eign com­pute, the Star­gate cam­pus), for health data and

Digital HealthState of Play33 •

re­search (Malaffi, the life-sci­ences clusters), and for the re­gional headquar­ters and op­er­a­tions of global firms.

The hub strategy is vis­ible in the fig­ures, and the fig­ures re­quire care. UAE di­gital health is put at about US$0.93 bil­lion in 2025, rising to about US$7.6 bil­lion by 2035 at about 23 per cent a year. That is the fast­est head­line rate in the re­gion, achieved from a base roughly one fifth the size of Saudi Ar­a­bia's (Mar­ket Re­search Fu­ture and na­tional series, 2026). A high growth rate on a small base is not the same thing as scale. The UAE's strategy is con­struc­ted on pre­cisely that re­cog­ni­tion.

The emir­ates' genu­ine lead is in the data layer. Three in­ter­con­nec­ted ex­changes, Malaffi in Abu Dhabi, NABIDH in Dubai and Riay­ati na­tion­ally, make roughly 1.9 bil­lion re­cords ac­cess­ible. NABIDH alone holds about 10.4 mil­lion re­cords across 1,888 fa­cil­it­ies, and Riay­ati con­nects about 5,000. In­teg­ra­tion is man­dat­ory for telemedi­cine pro­viders. No other Gulf state has as­sembled an equi­val­ent data layer, and it is the sub­strate on which clin­ical ar­ti­fi­cial in­tel­li­gence is built.

The payer po­s­i­tion is equally ad­vanced. Com­puls­ory cover for private-sec­tor work­ers and un­covered do­mestic em­ploy­ees took ef­fect on 1 Janu­ary 2025. Health premi­ums rose about 12.7 per cent in the first half of that year, and Dubai's eClaimLink, re­in­forced by dir­ect­ive PD-05-2025, en­forces elec­tronic claims under defined timelines. Against that, cap­ital flow re­mains sec­ond­ary to Saudi Ar­a­bia's. The UAE re­cor­ded about US$1.2 bil­lion of star­tup fund­ing in the third quarter of 2025 against the king­dom's

US$3.2 bil­lion, and 11 of the 32 fun­ded GCC health-tech­no­logy com­pan­ies to July 2026. The UAE leads on data, reg­u­la­tion and the payer rail, and fol­lows on scale and cap­ital.

The whole UAE digital-health market is smaller than one quarter of startup funding
US$ bn
024680.9Market, 20251.2Funding, Q3 20257.6Market, 2035
Source: Market Research Future and national series, 2026

Qatar and the smaller states

For the four small states, scale is not a challenge to overcome but a fact to design around.

Qatar, Kuwait, Oman and Bahrain meet the scale prob­lem in its most acute form. Pop­u­la­tions run from 1.6 to 5 mil­lion, too small to an­chor any con­sumer health-tech busi­ness or to jus­tify the ven­ture

Digital HealthState of Play34 •

eco­nom­ics of a private plat­form. Their re­sponse is ne­ces­sar­ily dif­fer­ent from Saudi Ar­a­bia’s plat­form-state or the UAE’s hub. They build na­tional di­gital-health in­fra­struc­ture for their own cit­izens and largely im­port or buy the tech­no­logy to do it. Qatar runs its na­tional re­cord on a global elec­tronic-health-re­cord sys­tem and, backed by the Qatar In­vest­ment Au­thor­ity’s vast re­sources, in­vests in high-value spe­cial­ised medi­cine. Kuwait launched a con­sol­id­ated na­tional health app in late 2025. Oman and Bahrain run na­tional sys­tems of their own.

StatePopulation (2024)Digital-health system
Qatar~3.2MNational record (global EHR); QIA-funded specialist medicine
Kuwait~5.0M“Salem” national app (2025)
Oman~5.3MAl-Shifa national EHR
Bahrain~1.6MI-SEHA national system

For these states the stra­tegic real­ity is that do­mestic scale is simply un­avail­able. The sov­er­eign-plat­form model is there­fore the only one that works. A na­tional sys­tem is built for a small pop­u­la­tion and fun­ded from the state, and no private mar­ket is ex­pec­ted to emerge at that size. Their lever­age, where they have it, lies in wealth per cap­ita (Qatar can buy fron­tier cap­ab­il­ity for a small, rich pop­u­la­tion) and in the pos­sib­il­ity of pool­ing with their neigh­bours, which the frag­ment­a­tion and data walls cur­rently pre­vent. The smal­ler states are the scale prob­lem in its purest form. They

are mar­kets too small for private di­gital health, served well by the sov­er­eign, and de­pend­ent on the state pre­cisely be­cause no other model works at their size. They are the clearest il­lus­tra­tion of why, in the Gulf, the an­swer to di­gital health is the gov­ern­ment, be­cause for four of the six states, there is no al­tern­at­ive.

The four smal­ler states dif­fer from one an­other more than their size sug­gests, and the dif­fer­ences de­term­ine the order in which they should be ap­proached. Bahrain is the agile, fin­ance-led mar­ket and the clean­est reg­u­lat­ory prov­ing ground. Its SEHATI scheme, es­tab­lished under Law 23 of 2018, car­ries an al­loc­a­tion of BD 688 mil­lion and cov­ers roughly 686,000 ex­pat­ri­ate res­id­ents and their de­pend­ants. The scheme re­mains in phased rol­lout rather than fully in force. Oman is earlier-stage and pub­lic-led, run­ning the Al Shifa na­tional elec­tronic med­ical re­cord, with its Dham­ani in­sur­ance plat­form launched on 1 Janu­ary 2025 and like­wise still phas­ing in.

Qatar is the premium, re­search-led mar­ket, run­ning its na­tional re­cord on an en­ter­prise sys­tem at Sidra Medi­cine, sup­por­ted by Qatar In­vest­ment Au­thor­ity cap­ital and a ge­n­om­ics pro­gramme. It also car­ries the re­gion's second-heav­iest dia­betes bur­den, at about 24.6 per cent of adults (In­ter­na­tional Dia­betes Fed­er­a­tion, 11th edi­tion, 2025). Kuwait is de­mand-rich and re­form-slow, with the highest pre­val­ence in the re­gion at about 25.6 per cent and the Das­man in­sti­tute as its re­search an­chor.

The stra­tegic read­ing is that these are payer-and-data-gated op­por­tun­it­ies to be ap­proached in­di­vidu­ally rather than a re­sid­ual block. Qatar buys

Digital HealthState of Play35 •

fron­tier cap­ab­il­ity for a small, wealthy pop­u­la­tion. Kuwait's dis­ease bur­den un­der­writes chronic-care de­mand that its re­form pace has yet to meet. Bahrain's agil­ity makes it a sens­ible first mar­ket for a reg­u­lated pilot. Oman's Dham­ani rol­lout is the de­vel­op­ment worth watch­ing, be­cause it is the clearest near-term test of whether the payer man­date ex­tends bey­ond the two large mar­kets.

The capital and the deals

The deal flow confirms the structure: sovereign money building platforms and buying scale abroad, not funding domestic startups.

The trans­ac­tions of re­cent years map the read’s struc­ture pre­cisely. The largest deals are sov­er­eign and in­ter­na­tional. Mi­crosoft put $1.5 bil­lion into G42, and HUMAIN and the UAE’s AI cam­puses carry multi-bil­lion-dol­lar AI-com­pute part­ner­ships. PureHealth’s near-bil­lion-dol­lar IPO was fol­lowed by its $1.2 bil­lion ac­quis­i­tion of a UK hos­pital group, and M42 was formed and ex­pan­ded in­ter­na­tion­ally. The money is vast and pa­tient, it is sov­er­eign, and it is poin­ted at plat­forms, com­pute and over­seas ac­quis­i­tion rather than at do­mestic con­sumer health-tech star­tups, which raise the tens of mil­lions doc­u­mented earlier.

Cap­ital al­loc­a­tion fol­lows the thesis ex­actly. Where scale prom­ises re­turns, in ex­port­able AI, in in­ter­na­tional ac­quis­i­tions, in na­tional in­fra­struc­ture the

state will fund re­gard­less, the money flows freely. Where scale is capped, in do­mestic con­sumer health-tech, private cap­ital stays away, and the gap is filled, if at all, by the sov­er­eign in­cub­at­ing ven­tures it­self. For an in­vestor, the im­plic­a­tion is to fol­low the sov­er­eign and the ex­port path. The value is in the state-built plat­forms, in the AI cham­pi­ons that scale by com­pute and reach abroad, and in the in­ter­na­tional ac­quis­i­tions that buy the scale the re­gion lacks at home. It is not in do­mestic con­sumer plays fight­ing free gov­ern­ment super-apps for a small pop­u­la­tion. The deals do not con­tra­dict the thesis. They ex­ecute it. Cap­ital goes where scale is, and in Gulf di­gital health, scale is found in AI, in the sov­er­eign, and abroad.

The deal re­cord is worth cit­ing in its own terms. The de­fin­ing trans­ac­tions of the period are stra­tegic or sov­er­eign-linked rather than clas­sic early-stage ven­ture. HUMAIN was formed as a Pub­lic In­vest­ment Fund ar­ti­fi­cial-in­tel­li­gence vehicle cap­it­al­ised at about US$10 bil­lion. M42 was cre­ated by Mubadala and G42 to com­bine care de­liv­ery with ap­plied ar­ti­fi­cial in­tel­li­gence. Aster DM's US$250 mil­lion myAster phar­macy joint ven­ture with Al Hokair cov­ers 186 phar­ma­cies across Saudi Ar­a­bia, and Klaim's US$26 mil­lion Series A in 2025 ran on the claims rail (com­pany and sov­er­eign-fund dis­clos­ures, 2025 to 2026).

The geo­graphic dis­tri­bu­tion of that flow is as con­cen­trated as the mar­ket it­self. Saudi Ar­a­bia took roughly 64 per cent of MENA star­tup cap­ital in the first half of 2025, and about US$3.2 bil­lion across 62 deals in the third quarter, against the UAE's US$1.2 bil­lion. The whole of dis­closed GCC

Digital HealthState of Play36 •
The largest transactions of the period are sovereign or international
US$ bn
HUMAIN vehicle10Microsoft into G421.5UK hospital group1.2
Source: company and sovereign-fund disclosures, 2025 to 2026

health-tech­no­logy ven­ture in­vest­ment amoun­ted to about US$148 mil­lion across 32 star­tups in the eight­een months to July 2026.

The route to scale is there­fore in­sti­tu­tional rather than com­pet­it­ive, and this is the prac­tical con­clu­sion for a founder or an in­vestor. Align­ment with the sov­er­eign and stra­tegic agenda is the more re­li­able path. That means the pub­lic rails, the in­surer re­la­tion­ships, part­ner­ship and even­tual ac­quis­i­tion. The al­tern­at­ive is an in­de­pend­ent ven­ture pipeline that the re­gion's cap­ital mar­kets do not yet sup­port at health-tech­no­logy scale. The deals are not evid­ence of a thriv­ing private mar­ket. They are evid­ence of a sov­er­eign mar­ket with a private peri­phery.

The 2026 res­ults con­firm where the re­turns are ac­tu­ally being earned. PureHealth lif­ted group rev­enue nine per cent to 14.9 bil­lion dirhams in the first half of 2026, with earn­ings be­fore in­terest, tax, de­pre­ci­ation and amort­isa­tion up 24 per cent to 2.9 bil­lion dirhams (PureHealth, 2026). In­ter­na­tional rev­enue rose 56 per cent to 5.0 bil­lion dirhams on the con­sol­id­a­tion of Hel­lenic Health­care Group in Greece and Cyprus, and over­seas

op­er­a­tions sup­plied a third of group rev­enue. Growth abroad out­ran growth at home. By the nine-month mark net profit stood at 1.8 bil­lion dirhams, higher by 14.1 per cent on the year.

Be­neath the sov­er­eign tier, the private rounds of 2026 stayed small and largely stra­tegic. TruDoc, which runs vir­tual-first primary care and a hos­pital-at-home pro­gramme in the Emir­ates and Saudi Ar­a­bia, raised 15 mil­lion dol­lars in a pre-Series B led by the Al Nahyan and Al-Ketbi fam­il­ies in March of that year (TruDoc, 2026). Ha­keem Health fol­lowed in May with 1.65 mil­lion dol­lars for clin­ical de­cision sup­port, led by Merak Cap­ital with San­abil 500 par­ti­cip­at­ing. Sov­er­eign-linked funds set the terms. Against the sov­er­eign cheques these are round­ing er­rors.

Two fea­tures of the 2026 re­cord bear dir­ectly on strategy. The first is that the in­surer rail now car­ries earn­ings of its own, Daman hav­ing writ­ten gross premium of 5.5 bil­lion dirhams in the first half, up 13 per cent, across an in­sured mem­ber­ship of 3.4 mil­lion (PureHealth, 2026). The second is that ac­quis­i­tion re­mains the pre­ferred in­stru­ment at home as well as abroad, six fa­cil­it­ies being bought from Aspen Clin­ics in Abu Dhabi and Al Ain in Novem­ber 2026. Cap­ab­il­ity is pur­chased rather than in­cub­ated. A founder should price that in from the out­set.

Digital HealthState of Play37 •

The part in brief

  1. 01The state app passed 31 million users and handled over 51 million consultations and appointments in 2024, in a country of about 35 million.
  2. 02The private layer is slight beside it: Cura reports more than 350,000 users, and GCC health-tech venture funding was about US$36.2 million in 2025.
  3. 03M42 employs more than 20,000 people across 450 facilities in 26 countries, because the home market cannot hold a champion of that size.
  4. 04PureHealth raised about $986 million at its December 2023 listing, then bought Britain's Circle Health for roughly $1.2 billion.
  5. 05Saudi digital health is put near US$4.4 billion for 2025 and the UAE near US$0.93 billion, of a regional US$6.28 billion.
Digital HealthState of Play38 •
The Players

For commercial players, the lesson is to integrate with or build for the super-app, not against it.

04

The Read

Why scale resists capital, where the value is, and where the market goes.

Why scale cannot be bought

The Gulf can buy almost anything for its health system. The one thing it cannot purchase is the size of its own population.

The deep­est con­clu­sion of this read is that scale is the one input sov­er­eign cap­ital can­not buy. The Gulf has shown that money can pur­chase first-rate plat­forms, the largest vir­tual hos­pital on earth, fron­tier AI com­pute, in­ter­na­tional hos­pital groups, the re­gional headquar­ters of every global health firm. It can fund uni­ver­sal cov­er­age, man­date in­sur­ance, and push a super-app to 31 mil­lion cit­izens. There is al­most noth­ing in health that Gulf cap­ital can­not ac­quire. The ex­cep­tions are a lar­ger pop­u­la­tion and a uni­fied mar­ket.

That is why the scale con­straint is so fun­da­mental and so res­ist­ant. A payer can be le­gis­lated; cap­ital can be de­ployed; plat­forms can be built; tal­ent can be im­por­ted. But the num­ber of people in the six states, and the bor­ders that di­vide them, are facts cap­ital can­not change. The Gulf can buy scale abroad, PureHealth in Bri­tain, M42 across 26 coun­tries. It can also tran­scend scale through AI that ex­ports bey­ond the re­gion. What it can­not do is con­jure a do­mestic mass mar­ket where the demo­graphy does not provide one. The everything-but-scale con­di­tion is not a phase the Gulf will spend its way out of. It is a struc­tural fea­ture of a wealthy and small re­gion, and a frag­men­ted one. The stra­tegic re­sponse is not to wait

for scale to ar­rive but to build where scale mat­ters least, the sov­er­eign plat­form, the AI layer, the in­ter­na­tional ex­pan­sion. The one thing the Gulf’s wealth can­not man­u­fac­ture is do­mestic con­sumer scale.

The Gulf can buy a virtual hospital, frontier AI, and a hospital group in Britain. It cannot buy a larger population, and that is the whole story.

The re-based mar­ket series makes the point more force­fully than the ori­ginal did. On the su­per­seded basis, com­pound­ing at about 21 per cent a year, the Gulf would have grown its way to­wards a sub­stan­tial mar­ket within a dec­ade. On the cur­rent basis the re­gion is put at about US$23.8 bil­lion by 2035, grow­ing at about 14.2 per cent from about US$6.28 bil­lion in 2025 (Mar­ket Re­search Fu­ture, 2026). Growth above 20 per cent sur­vives only in Saudi Ar­a­bia and the UAE taken sep­ar­ately. The re­vi­sion mat­ters be­cause it re­moves the one an­swer to the scale prob­lem that re­quired no strategy. That an­swer was wait­ing.

Scale is not the only un­buyable input. Clin­ical and en­gin­eer­ing tal­ent in the Gulf is scarce, con­tested and largely im­por­ted, and it can­not be le­gis­lated into ex­ist­ence any more than pop­u­la­tion can. The stand­ing mit­ig­a­tion is part­ner­ship with sov­er­eign and aca­demic in­sti­tu­tions along­side de­lib­er­ate im­port­a­tion and train­ing, which is a pro­gramme meas­ured in years rather than a trans­ac­tion meas­ured in months. A re­gion that can com­mis­sion a

Digital HealthState of Play39 •

vir­tual hos­pital con­nect­ing 241 hos­pit­als and more than 1,400 health centres can­not com­mis­sion the clini­cians to staff the sys­tem be­hind it.

What cap­ital does buy, it buys out­right, and the dis­tinc­tion is worth hold­ing. It buys plat­forms and com­pute, pooled re­cords and reg­u­lat­ory ca­pa­city, and for­eign hos­pital groups. It does not buy pop­u­la­tion. It does not dis­solve the three health-data re­gimes that di­vide the re­gion, and it does not shorten the time re­quired to train a work­force. The stra­tegic re­sponse is to build where those three ab­sences do not bind, which is the sov­er­eign plat­form, the ar­ti­fi­cial-in­tel­li­gence layer and the in­surer rail.

Two of six markets

A blunt strategic simplification cuts through the fragmentation: in practice, the Gulf is two markets, not six.

For all the talk of six states, the prac­tical real­ity for a di­gital-health player is that the Gulf is two mar­kets that mat­ter and four that mostly do not. Saudi Ar­a­bia and the UAE to­gether hold the great ma­jor­ity of the re­gion’s pop­u­la­tion. They hold an even lar­ger share of its health spend­ing, around 83%, and ef­fect­ively all of its scale, cap­ital, plat­forms and AI cap­ab­il­ity. Qatar, Kuwait, Oman and Bahrain are small. They are well-served by their own sov­er­eign sys­tems, and in­di­vidu­ally too minor to an­chor a

re­gional strategy. The hon­est stra­tegic map of Gulf di­gital health has two an­chors and four foot­notes.

The sim­pli­fic­a­tion cla­ri­fies the op­por­tun­ity and the limit. The op­por­tun­ity is that a player ser­i­ous about the Gulf can con­cen­trate on two mar­kets, the Saudi plat­form state and the UAE hub, and cap­ture most of the avail­able value without the cost of six sep­ar­ate mar­ket entries. The limit is that even those two, com­bined, are about 47 mil­lion people across two sep­ar­ate reg­u­lat­ory and data re­gimes. That is mean­ing­ful, but still a frac­tion of one large emer­ging mar­ket, and still di­vided. The two-of-six fram­ing does not solve the scale prob­lem (two small mar­kets are not one large one) but it fo­cuses it. The Gulf di­gital-health op­por­tun­ity is, in prac­tice, a Saudi-and-UAE op­por­tun­ity, pur­sued through the sov­er­eign and the AI layer. It is best un­der­stood as two rich, capped mar­kets rather than one re­gion of six. For most play­ers, the smal­ler four are not where the strategy lives.

The two-mar­ket con­cen­tra­tion can be stated on the mar­ket's own fig­ures rather than on the health-spend­ing proxy, and the res­ult is firmer. Saudi di­gital health is put at about US$4.4 bil­lion in 2025 and UAE di­gital health at about US$0.93 bil­lion, against a re-based re­gional total of about US$6.28 bil­lion for the same year. The two mar­kets there­fore ac­count for roughly 85 per cent of Gulf di­gital-health spend (Mar­ket Re­search Fu­ture and na­tional series, 2026). The re­main­ing four states di­vide about US$1 bil­lion between them. That is below the threshold at which a ded­ic­ated mar­ket entry re­cov­ers its own com­pli­ance cost.

Digital HealthState of Play40 •
Digital-health market by territory, 2025
US$ bn
024686.3GCC, whole4.4Saudi Arabia0.9UAE
Source: Market Research Future and national series, 2026

The con­cen­tra­tion holds on the cap­ital side as well. Of the 32 GCC health-tech­no­logy com­pan­ies that raised dis­closed fund­ing between Janu­ary 2025 and July 2026, 17 were Saudi and 11 were from the UAE, leav­ing four across the other states com­bined (PitchBook, via WHX Tech, 2026). De­mand, plat­forms, cap­ital and deal flow con­cen­trate in the same two mar­kets, which is un­usual: these vari­ables di­verge in most re­gions.

The sim­pli­fic­a­tion is non­ethe­less a fo­cus­ing device rather than a solu­tion, and the arith­metic should be kept in view. Two mar­kets of about US$5.3 bil­lion com­bined, gov­erned by sep­ar­ate reg­u­lat­ors and sep­ar­ate health-data re­gimes, do not con­sti­tute one mar­ket of that size. The in­teg­ra­tion and com­pli­ance costs are in­curred twice, while the growth rates, at about

22 and 23 per cent re­spect­ively, apply to two sep­ar­ate bases. The Gulf op­por­tun­ity is a Saudi-and-UAE op­por­tun­ity, pur­sued twice.

The four smaller states divide about a billion dollars between them
US$ bn, 2025
024686.3GCC, whole5.3Saudi and UAE1Other four
Source: Market Research Future and national series, 2026
For most players, the smaller four are not where the strategy lives.

These con­straints share a char­ac­ter. Like scale, they are struc­tural rather than fix­able by a single de­cision, and sev­eral are the price of the very sov­er­eignty that makes the Gulf model work. Data loc­al­isa­tion re­flects genu­ine se­cur­ity con­cerns; ex­pat­ri­ate de­pend­ence re­flects small na­tional pop­u­la­tions; fiscal de­pend­ence re­flects the re­source base that funds everything. They are not fail­ures of ex­e­cu­tion but fea­tures of the re­gion’s

Digital HealthState of Play41 •

situ­ation, which is a small and wealthy cluster of states, re­source-de­pend­ent and con­scious of its sov­er­eignty. They do not neg­ate the Gulf’s genu­ine ad­vant­ages, but they bound them, and they ex­plain why the everything-but-scale con­di­tion is dur­able. The Gulf’s di­gital-health strengths and its con­straints flow from the same source. It is rich and small, sov­er­eign and di­vided.

The constraints beyond scale

Scale is the binding constraint, but it does not stand alone: four others compound it.

Scale is the de­fin­ing con­straint, but an hon­est read names the oth­ers that com­pound it:

  • Frag­ment­a­tion and data loc­al­isa­tion. Six sep­ar­ate reg­u­lat­ors and na­tional data-res­id­ency rules pre­vent a single re­gional plat­form, sli­cing the small mar­ket into smal­ler sealed ones: the mul­ti­plier on the scale prob­lem.
  • Im­por­ted tech­no­logy. The sov­er­eign-com­pute ad­vant­age runs en­tirely on im­por­ted sil­icon under for­eign ex­port con­trols; the Gulf leads in de­ploy­ing AI, not in mak­ing the hard­ware be­neath it.
  • Ex­pat­ri­ate tal­ent. The health and tech­no­logy work­force is over­whelm­ingly im­por­ted and mo­bile, mak­ing both the health sys­tem and the di­gital-health in­dustry de­pend­ent on tal­ent that can leave.
  • Fiscal de­pend­ence. The en­tire build-out rests on oil rev­enue; a sus­tained price fall would pres­sure the sov­er­eign spend­ing that funds the plat­forms and the com­pute.

Two of the four con­straints can be stated more pre­cisely, and a fifth should be added. The frag­ment­a­tion con­straint is a mat­ter of seven health reg­u­lat­ors and three sep­ar­ate health-data re­gimes rather than six of each. The ad­di­tional reg­u­lator arises from the UAE's split of au­thor­ity between fed­eral and emir­ate level. The tal­ent con­straint is not only a de­pend­ence on im­por­ted staff but a con­test for it. Clin­ical and en­gin­eer­ing tal­ent is scarce across all six states sim­ul­tan­eously, so the states com­pete with one an­other and with the private sec­tor for the same pool.

The fifth con­straint is de­pend­ence on the state's pace. Where dis­tri­bu­tion, the data layer and in­creas­ingly the payer rail are pub­lic, a private op­er­ator's roadmap is partly de­term­ined by a min­istry's, and the rails dif­fer by coun­try so the de­pend­ency is in­curred sep­ar­ately in each. The stand­ing mit­ig­a­tion is di­ver­si­fic­a­tion of chan­nel rather than of geo­graphy: an op­er­ator earn­ing rev­enue from in­surers, em­ploy­ers and hos­pital sys­tems along­side the pub­lic plat­form is less ex­posed than one whose dis­tri­bu­tion runs through a single pro­gramme.

The char­ac­ter these con­straints share is that each is the cost of some­thing the re­gion val­ues. Data loc­al­isa­tion is the price of data sov­er­eignty; im­por­ted tal­ent is the con­sequence of small na­tional pop­u­la­tions; de­pend­ence on the state is the coun­ter­part of re­ceiv­ing dis­tri­bu­tion and trust as pub­lic

Digital HealthState of Play42 •

in­fra­struc­ture. None is an ex­e­cu­tion fail­ure. None is re­mov­able by a single de­cision. The con­straints and the ad­vant­ages in this mar­ket are gen­er­ated by the same facts, which is why the con­di­tion this read de­scribes is dur­able rather than trans­itional.

Market access, and what could go wrong

For the right kind of player, the Gulf is an exceptional market: provided the strategy fits the scale.

For a di­gital-health player whose model fits the Gulf’s shape, the re­gion is among the most at­tract­ive in the world. There is a pay­ing payer and abund­ant cap­ital, clear tele­health reg­u­la­tion and acute de­mand. The vi­able strategies fol­low straight from the read. Build for or with the sov­er­eign plat­forms rather than against them. Sup­ply or power the gov­ern­ment super-apps and vir­tual hos­pit­als, or in­teg­rate with them. Serve the en­ter­prise and in­surer layer, where the payer pays, rather than chas­ing con­sumers against free state apps. Lead with AI, which scales by com­pute and ex­port, not do­mestic users. And con­cen­trate on Saudi Ar­a­bia and the UAE, the two mar­kets with the scale and cap­ital that mat­ter.

Three risks could bend the tra­ject­ory. Fiscal de­pend­ence is the deep­est: the sov­er­eign spend­ing that funds the plat­forms and the com­pute rests on

oil, and a sus­tained price fall would slow it. The crowding-out dy­namic could in­tensify, the state tak­ing ever more of the space and leav­ing private play­ers a shrink­ing edge. And the frag­ment­a­tion could per­sist or harden, keep­ing the mar­kets sealed and cap­ping the re­gional scale that might one day off­set small pop­u­la­tions. None of these re­verses the Gulf’s struc­tural ad­vant­ages (the payer, the cap­ital, the de­mand and the AI lead are real and dur­able), but each shapes who cap­tures the value, and how. The Gulf is not a mar­ket to enter with a con­sumer-scale play­book; it is a mar­ket to enter with a sov­er­eign-and-AI play­book, sized to two rich mar­kets rather than one large one.

Key takeaways: access
  • Build for or with the sov­er­eign plat­forms, not against the free state super-apps.
  • Serve the en­ter­prise/in­surer layer and AI, which scale by payer and com­pute, not do­mestic users.
  • Con­cen­trate on Saudi Ar­a­bia and the UAE: the two mar­kets with the scale and cap­ital.

The vi­able chan­nels can be ranked, and the rank­ing is un­am­bigu­ous on eco­nom­ics. The in­surer and em­ployer chan­nel of­fers the strongest po­s­i­tion. Cover is com­puls­ory, group cover is em­ployer-fun­ded and re­cur­ring, and the claims rail is en­forced, so rev­enue is payer-fun­ded and re­peat­ing. Pub­lic-plat­form in­teg­ra­tion fol­lows, sup­ply­ing low-cost reach and in­ter­op­er­ab­il­ity at the state's pace. The pro­vider and hos­pital chan­nel is sticky

Digital HealthState of Play43 •

and in­teg­ra­tion-led but car­ries a long sales cycle. Dir­ect-to-con­sumer is last. It is vi­able only for premium or spe­ci­al­ity pro­pos­i­tions or for a plat­form already ag­greg­ated across the re­gion, be­cause ac­quis­i­tion cost is high and the do­mestic audi­ence in any one state is small.

The entry se­quence fol­lows from the mar­ket's con­cen­tra­tion. Build for Saudi Ar­a­bia and the UAE first, where the de­mand, the plat­forms and the cap­ital are. In­teg­rate with the pub­lic rails and the in­surer from the out­set rather than ret­ro­fit­ting. And ap­proach Bahrain, Qatar, Kuwait and Oman as sep­ar­ate payer-and-data-gated op­por­tun­it­ies, tak­ing Bahrain first for its reg­u­lat­ory agil­ity and watch­ing Oman's Dham­ani rol­lout as the test of whether the man­date spreads.

The risk re­gister is cor­res­pond­ingly spe­cific. Com­pet­i­tion from free pub­lic plat­forms is mit­ig­ated by spe­cial­isa­tion and in­teg­ra­tion rather than by price. Data sov­er­eignty across three re­gimes is mit­ig­ated by ar­chi­tect­ing for loc­al­isa­tion from the start, which is ex­pens­ive to ret­ro­fit and cheap to design in. Tal­ent scarcity is mit­ig­ated through sov­er­eign and aca­demic part­ner­ship. De­pend­ence on state pace is mit­ig­ated by chan­nel di­ver­si­fic­a­tion. Each is man­age­able, and none is avoid­able.

The provider and hospital channel is sticky and integration-led but carries a long sales cycle.

The next two to three years

What a player or investor should expect Gulf digital health to look like by 2028.

Over the next two to three years Gulf di­gital health will deepen along the same lines. It will be sov­er­eign-led and AI-for­ward, and bounded by scale. Four de­vel­op­ments are most likely:

  • The sov­er­eign plat­forms ex­pand. Seha Vir­tual Hos­pital, the super-apps and the na­tional re­cords grow and add AI, con­sol­id­at­ing the state’s own­er­ship of the most valu­able di­gital-health as­sets.
  • AI be­comes the centre of grav­ity. Sov­er­eign com­pute and clin­ical mod­els (Med42 and suc­cessors) make AI the area where the Gulf genu­inely leads and ex­ports: the layer that es­capes the scale ceil­ing.
  • Cham­pi­ons scale abroad. M42, PureHealth and their peers keep ac­quir­ing and ex­pand­ing in­ter­na­tion­ally, be­cause growth lives out­side the re­gion, not within it.
  • The private layer stays niche. Do­mestic con­sumer health-tech re­mains thin; private value con­cen­trates in en­ter­prise, in­surer and sov­er­eign-sup­plier roles, not con­sumer scale.

The bind­ing ques­tion stays scale, and it will not re­solve, be­cause demo­graphy and bor­ders do not change on a three-year ho­ri­zon. The Gulf will keep build­ing the best-fun­ded, best-reg­u­lated, most AI-ad­vanced

Digital HealthState of Play44 •

di­gital-health sys­tem in the emer­ging world. It will keep doing it through the sov­er­eign, for small mar­kets, with private cham­pi­ons reach­ing abroad for the scale home can­not give. The smart po­s­i­tion, for player and in­vestor alike, is to treat the Gulf as what it is. It is a sov­er­eign-and-AI mar­ket, ex­cep­tion­ally re­sourced and struc­tur­ally capped, where value ac­crues to who­ever builds for the state and the AI layer and looks abroad for scale. It is not a mar­ket in which to scale a con­sumer busi­ness.

The growth ex­pect­a­tion should be re-based be­fore the fore­casts are read. The re­gional series now com­pounds at about 14.2 per cent to 2035 rather than the roughly 21 per cent on which this read was first con­struc­ted. The dec­ade ahead is there­fore slower in ag­greg­ate than pre­vi­ously pro­jec­ted. The fast­est seg­ments re­main well above the re­gional rate. Tele­health is at about 21.9 per cent to 2033, and the two lead­ing na­tional mar­kets at about 22 and 23 per cent (Mar­ket Re­search Fu­ture, IMARC and Pre­ced­ence Re­search, 2024 to 2026). Growth in Gulf di­gital health is now a seg­ment and coun­try story rather than a re­gional one.

Four de­vel­op­ments are worth watch­ing spe­cific­ally, be­cause each is dated. Oman's Dham­ani plat­form, launched on 1 Janu­ary 2025, and Bahrain's SEHATI are both still phas­ing in, so the next two years de­term­ine whether the payer man­date ex­tends bey­ond Saudi Ar­a­bia and the UAE. Saudi en­force­ment of the Per­sonal Data Pro­tec­tion Law is in­tensi­fy­ing, with 48 breach de­cisions is­sued by mid-Janu­ary 2026 and sec­tor audits in health­care re­por­ted from the second quarter of that year. That raises the

Compound annual growth, by series
per cent a year
UAE digital health, to 203523Saudi digital health, to 203222GCC telehealth, to 203321.9GCC e-health, to 203315.6GCC e-pharmacy, to 203315.4GCC digital health, to 203514.2
Source: Market Research Future, IMARC and Precedence Research, 2024 to 2026

com­pli­ance floor for every op­er­ator hold­ing Gulf health data. The pub­lic plat­form layer con­tin­ues to deepen, Seha hav­ing been re­launched in March 2025 on an ex­pan­ded model. And the ven­ture layer re­mains thin, at about US$148 mil­lion dis­closed across 32 com­pan­ies to July 2026.

The bind­ing ques­tion will not re­solve on this ho­ri­zon. Pop­u­la­tion and bor­ders do not change in three years, and the re-based growth rate re­moves the pro­spect of out­grow­ing them.

What it lacks is scale. There are 61.2 mil­lion people across six sep­ar­ately-reg­u­lated states, with data-loc­al­isa­tion walls block­ing a single re­gional plat­form and a tran­si­ent, ex­pat­ri­ate-heavy pop­u­la­tion. That single ab­sence re­shapes everything. It caps con­sumer health-tech eco­nom­ics (GCC health-tech ven­ture fund­ing was about $36 mil­lion in 2025), con­cen­trates value in sov­er­eign-built plat­forms and the AI layer, and pushes the

Digital HealthState of Play45 •

re­gion’s cham­pi­ons to ac­quire scale abroad. The Gulf solved the payer and cap­ital prob­lems. It can­not solve the scale prob­lem, be­cause scale is the one input sov­er­eign wealth can­not buy.

The read, on a page

The argument, restated with the evidence behind it.

The Gulf has every in­gredi­ent di­gital health needs ex­cept one. It has a rich in­sti­tu­tional payer, uni­ver­sal state care plus man­dat­ory in­sur­ance, with tele­health re­im­bursed at par­ity, that solves the unit-eco­nom­ics prob­lem crip­pling di­gital health else­where. It has bot­tom­less sov­er­eign cap­ital. Its AI com­pute is among the largest any­where. It has gov­ern­ment-built plat­forms at na­tional scale, from the world’s largest vir­tual hos­pital to na­tional re­cord ex­changes. And it has acute de­mand, driven by one of the heav­iest dis­ease bur­dens on earth and a short­age of clini­cians. By every meas­ure that gates di­gital health in India or Africa, the Gulf is rich.

The Gulf has everything digital health needs except scale, and value accrues to those who build for the sovereign and the AI layer, not the consumer.

For the player and the in­vestor, the read is to fit the strategy to the struc­ture. Build for the sov­er­eign plat­forms and the AI layer. Serve the payer and the en­ter­prise, con­cen­trate on Saudi Ar­a­bia and the UAE, and look abroad for the scale the re­gion can­not provide.

Three of the fig­ures on which this read rests have been re-stated. The mar­ket basis is now about US$6.28 bil­lion in 2025, reach­ing about US$23.8 bil­lion by 2035 at about 14.2 per cent a year. That su­per­sedes the roughly US$5.41 bil­lion at about 21 per cent on which the ar­gu­ment was first built, with growth above 20 per cent sur­viv­ing only in Saudi Ar­a­bia and the UAE taken sep­ar­ately (Mar­ket Re­search Fu­ture, 2026). The pub­lic plat­form is re­cor­ded at 241 hos­pit­als and more than 1,400 health centres (Saudi Min­istry of Health, 9 Au­gust 2026). And the dis­ease bur­den has been re-based to the In­ter­na­tional Dia­betes Fed­er­a­tion's 11th edi­tion, pub­lished in 2025 on 2024 es­tim­ates, giv­ing a Gulf range of 18.7 to 25.6 per cent of adults against a global 11.1 per cent.

None of the three weak­ens the ar­gu­ment, and the first strengthens it. A mar­ket com­pound­ing at 14 per cent rather than 21 per cent has less pro­spect of grow­ing past its own con­straint, so the scale prob­lem is more bind­ing on the cur­rent basis than on the su­per­seded one. The dis­ease bur­den is heav­ier and more evenly spread than pre­vi­ously stated, and the plat­form is wider.

The payer, mean­while, is ar­riv­ing un­evenly: com­puls­ory in the UAE from 1 Janu­ary 2025 and re­quired of every Saudi private em­ployer, but still

Digital HealthState of Play46 •
The 2025 basis is re-stated upward and the compounding re-stated down
US$ bn
06.212.518.8255.42025, superseded6.32025, re-based23.82035, re-based
Source: Market Research Future, 2026
No Gulf state sits within twice the global diabetes rate
per cent of adults
07.51522.53011.1Global18.7Gulf, lowest state25.6Gulf, highest state
Source: International Diabetes Federation

phas­ing in through Bahrain's SEHATI and Oman's Dham­ani. The read there­fore holds in its cor­rec­ted form. Everything but scale, with the scale con­straint tighter, the de­mand heav­ier, and the payer ad­vant­age con­cen­trated in the same two mar­kets as everything else.

Key takeaways

Nine conclusions for the people who must act on this market.

  1. The Gulf has everything but scale. Rich payer, sov­er­eign cap­ital, top-down plat­forms, acute de­mand: every in­gredi­ent ex­cept mar­ket size.
  2. The payer prob­lem is solved. State care plus man­dat­ory in­sur­ance, with tele­health re­im­bursed at par­ity: the op­pos­ite of India.
  3. Scale is the bind­ing con­straint. 61.2m people across six sep­ar­ately-reg­u­lated states: the one input cap­ital can­not buy.
  4. Data loc­al­isa­tion seals the mar­kets. Na­tional data-res­id­ency rules pre­vent a single re­gional plat­form, sli­cing a small mar­ket into smal­ler ones.
  5. The state is the dom­in­ant com­pany. Gov­ern­ment builds the super-apps, the vir­tual hos­pital and the re­cords: private play­ers build around it.
  6. The fund­ing gap proves it. ~$36m of GCC health-tech VC in 2025 against bil­lions in sov­er­eign com­pute: money is not the prob­lem, scale is.
  7. AI is where the Gulf leads. Com­pute and cap­ital, not users, drive AI: the layer that es­capes the scale ceil­ing and ex­ports.
Digital HealthState of Play47 •
  1. Cham­pi­ons scale abroad. M42 and PureHealth grow in­ter­na­tion­ally be­cause the do­mestic mar­ket is too small.
  2. It is two mar­kets, not six. Saudi Ar­a­bia and the UAE hold ~83% of the value: con­cen­trate there, through the sov­er­eign and the AI layer.

Volge's expertise in digital health

The engineering work the sector asks for, and the form it takes on an engagement.

Di­gital health in the Gulf is built on na­tional plat­forms and a state payer, so the en­gin­eer­ing it needs is in­teg­ra­tion, as­sur­ance and op­er­a­tions rather than con­sumer growth. The work below is what pro­viders, pay­ers and plat­form op­er­at­ors in this mar­ket com­mis­sion. Each is de­livered by senior en­gin­eers work­ing in­side the cli­ent's own team, with the Global De­liv­ery Centres run­ning what has been built once it is in pro­duc­tion.

Read­i­ness here is a gov­ernance ques­tion be­fore it is an en­gin­eer­ing one. The buyer who knows who owns pa­tient iden­tity, and where con­sent sits, can scope an in­teg­ra­tion in weeks, while the one who does not spends a quarter find­ing out. Own­er­ship of the na­tional in­ter­faces usu­ally sits

with one team and the clin­ical re­cord with an­other. That split is where pro­grammes stall. Volge asks for it to be settled in writ­ing at the out­set, be­cause en­gin­eer­ing can­not close an un­as­signed de­cision.

En­gage­ments of this kind are staffed thin at the top and deep in the middle. A prin­cipal ar­chi­tect car­ries the reg­u­lat­ory and in­teg­ra­tion design, stays ac­count­able for it after go-live, and does not ro­tate off, be­cause con­form­ance reas­on­ing is not trans­fer­able in a han­dover doc­u­ment. Below sit en­gin­eers who hold the na­tional pro­files and the run­books. Gov­ernance runs weekly against a single plan. A re­port­ing pack is not a plan.

Con­form­ance here is an evid­en­tiary ob­lig­a­tion, not a gate passed once. In­teg­ra­tion with a na­tional ex­change rests on pub­lished pro­files of Fast Health­care In­ter­op­er­ab­il­ity Re­sources, and a plat­form cer­ti­fied against last year's ver­sion of them is not cer­ti­fied (Health Level Seven In­ter­na­tional, 2019). The pro­files keep mov­ing. The prac­tical an­swer is a test har­ness the cli­ent owns, run on every re­lease, so that evid­ence is pro­du­cible on re­quest. Volge builds that har­ness dur­ing the first in­teg­ra­tion rather than after the first audit.

The first ninety days de­cide whether the rest of a pro­gramme is af­ford­able. The open­ing month es­tab­lishes where a cli­ent ac­tu­ally stands against each reg­u­lator, tested in the run­ning sys­tems, not read off a doc­u­ment. The second settles iden­tity and con­sent, which gate everything down­stream, and the third de­liv­ers one in­teg­ra­tion end to end, in pro­duc­tion, for a small clin­ical pop­u­la­tion. Noth­ing lar­ger is at­temp­ted. A pro­gramme that

Digital HealthState of Play48 •

can­not show a live in­ter­face by that quarter's close has a design prob­lem, not a re­sourcing one.

Meas­ure­ment should be clin­ical and op­er­a­tional, not a count of in­ter­faces de­livered. The use­ful num­bers are the share of en­coun­ters reach­ing the na­tional re­cord without manual re­pair, and the time taken to on­board a new fa­cil­ity, both re­port­able from the first re­lease. Three fail­ures recur. Pro­grammes treat con­sent as a screen rather than an ar­chi­tec­ture, and they buy a plat­form cer­ti­fied in an­other mar­ket as­sum­ing the cer­ti­fic­a­tion travels. Run and op­er­ate is left to last, which is where the cost of the first two ap­pears.

Connecting to the national rails
  • In­teg­ra­tion with the na­tional health ex­changes and uni­fied re­cord, through HL7 FHIR pro­files.
  • Pa­tient iden­tity and re­cord match­ing across pro­viders and emir­ates.
  • Con­sent and data-res­id­ency ar­chi­tec­ture that sat­is­fies each reg­u­lator sep­ar­ately.
  • Ter­min­o­logy and cod­ing ser­vices, so re­cords re­main com­par­able across sys­tems.
Care delivery platforms
  • Vir­tual care and tele­con­sulta­tion plat­form en­gin­eer­ing, in­clud­ing li­cens­ing con­trols.
  • Re­mote mon­it­or­ing for chronic dis­ease, from device in­ges­tion to clin­ical work­flow.
  • Clin­ical de­cision sup­port and ar­ti­fi­cial-in­tel­li­gence val­id­a­tion, with model gov­ernance.
  • Phar­macy and pre­scrip­tion sys­tems built to the reg­u­lator's con­trols.
The commercial layer
  • Claims and rev­enue-cycle auto­ma­tion across payer and pro­vider.
  • Ana­lyt­ics on util­isa­tion and out­comes, built for a payer that funds the care.
  • In­ter­op­er­ab­il­ity as­sur­ance and con­form­ance test­ing be­fore go-live.
  • Plat­form op­er­a­tions and ser­vice man­age­ment once the sys­tem is live.
How an engagement runs
  • A dia­gnosis of two to eight weeks, led on site by senior ar­chi­tects, es­tab­lish­ing where a pro­vider stands against each reg­u­lator.
  • A se­quenced pro­gramme, be­cause iden­tity and con­sent have to be settled be­fore any ex­change in­teg­ra­tion is use­ful.
  • Build teams em­bed­ded along­side the cli­ent's own en­gin­eers rather than work­ing to a spe­cific­a­tion at arm's length.
  • Run and op­er­ate from the Global De­liv­ery Centres, with con­form­ance evid­ence main­tained as the na­tional pro­files move.
Digital HealthState of Play49 •
The Read

The Gulf has everything digital health needs except scale, and value accrues to those who build for the sovereign and the AI layer, not the consumer.

Sources

The bodies cited in this read for market, funding, disease and regulatory figures, with the year the text attributes to each.

Digital HealthState of Play50 •
Version · VSP-GDH-001 · 2026
volgeEnable Powerful
Transformations
About Volge

Volge is an engineering firm providing enterprise technology transformation services to clients across the Middle East, India, APAC, Europe, and North America.

Delivery stands on two pillars: Forward Deployed Engineering, with senior specialists embedded in the client’s own team, and Intelligent Command Centre Operations, run from our Global Delivery Centres, which keeps what they build running. Senior engineers stay with an engagement from the first diagnosis through to production.

Our services span Strategy, Data, Platforms, AI and Automation, Cyber Trust, Technology Operations, and Applied Functional Engineering. Engagements begin with a diagnosis. The firm is built on working autonomy: engineers decide, innovate, co-create, and own their work. Motivated engineers build the systems that sustain our clients’ growth.

Terms of use

This edition may be shared with organisations evaluating a Volge engagement. It may not be altered or republished without Volge’s permission, and figures carry their stated basis and date. Volge, Intelligent Command Centre, and Intelligent Command Centre Operations are marks of Volge; other names are the trademarks of their respective owners.